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ABSTRACT
Introduction: Comprehensive pain assessment depends on the use of psychometrically valid
patient-reported outcome measures (PROMs). The Brief Pain Inventory-Short Form (BPI-SF)
and Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) are general-use
multidimensional pain assessment tools commonly used in musculoskeletal conditions.
Understanding all relevant measurement properties supports stronger decisions about PROMs.
Thesis Objectives: The overarching objective of this thesis was to determine the sufficiency
of measurement evidence backing the use of the BPI-SF and SF-MPQ-2 in musculoskeletal
conditions. Specifically, a systematic review was conducted to locate, summarize and
compare the quality and content of psychometric evidence backing the BPI-SF and SF-MPQ2 in musculoskeletal conditions. Based on this review, the gap in evidence regarding the
reliability and agreement properties (reproducibility) of SF-MPQ-2 was examined among
patients with musculoskeletal shoulder pain.
Methods: For the systematic review, we searched four databases to identify relevant citations.
Two reviewers independently screened, extracted and appraised (using MacDermid and
COSMIN guidelines) all psychometric reports on both tools in musculoskeletal conditions. To
determine the SF-MPQ-2 reproducibility, a convenience sample of adults diagnosed with
musculoskeletal shoulder pain (baseline, n=195; test-retest, n=48) completed the SF-MPQ-2
twice. Cronbach alpha (α), intraclass correlations coefficient (ICC2,1), agreement parameters
(SEM, MDC) and Bland-Altman plots were assessed.
Results: High quality evidence indicated both tools have high internal consistency (α = 0.830.96); and that they are moderately related (r = 0.3-0.69) to other health-related outcome
measures. More studies of better quality have evaluated the BPI-SF responsiveness (n=5),
retest reliability (n=3), known group validity (n=2) and structural validity (n=3), compared to
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the SF-MPQ-2. Our analysis of the SF-MPQ-2 reproducibility established internal consistency
as satisfactory (α, 0.83-0.95), relative reliability as good (neuropathic, intermittent, and
affective subscales: 1CC2,1= 0.78 - 0.88) to excellent (total and continuous subscale scores:
1CC2,1= 0.92 - 0.95). Agreement was within acceptable limits and there was no evidence of
systematic bias.
Conclusion: A greater volume of evidence of better quality currently supports the BPI-SF
although emerging evidence suggest the SF-MPQ-2 has excellent reliability and agreement
properties when used to assess adults with musculoskeletal shoulder pain. Direct comparisons
of the two scales in different contexts are needed.
Keywords: Brief Pain Inventory; Musculoskeletal Conditions; McGill Pain Questionnaire;
Reliability; Psychometric Properties; Reproducibility; Systematic Review
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LAY ABSTRACT

What is the problem? Musculoskeletal (MSK) refers to anything related to our muscles,
tendons, joints and connective tissue. Pain that comes from any of these tissues is called MSK
pain. MSK pain is one of the most common reasons people seek treatment from a doctor or
therapist, so the better we understand this pain, the better decisions we can make about
treatment. An important way of measuring MSK pain is by asking the person to give ratings
for different aspects of their pain using tools called patient-reported outcome measures (or
PROMS for short). Health care providers use PROMs for pain assessment because they are
simple and affordable. But more important, they give accurate scores that help monitor
treatment progress from the person’s own view. Researchers and health care providers need to
know which tools are best for MSK pain, especially when they are used to assess more than
one condition, like fractures and tendonitis.

Study question: The key question in my thesis work was: is there enough good evidence that
researchers and health care providers can feel confident using the Brief Pain Inventory ShortForm (BPI-SF) and Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) for
measuring MSK pain?

How did we study the problem? We did a careful search of online libraries of health science
research to find every study we could that told us about both tools. We recorded all the key
information about how well they measured MSK pain. Then, we assessed and compared the
quality of these studies, so we knew what information was best. In our second study, we
checked if the SF-MPQ-2 gave us the same (reliable) scores when it was used by patients
coming to see a doctor because of shoulder pain at two different times.
What did we learn? After all these studies, we concluded that the BPI-SF currently has more
good quality evidence backing its use in MSK condition than the SF-MPQ-2. We are also
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confident that SF-MPQ-2 will probably be a good tool for measuring MSK shoulder pain
since it yields consistent scores from our evaluation.
What do we still not know? Researchers and health care providers who want to use these
tools should be aware that they are not yet the ‘gold standard’. More research is needed to
confirm some of their measurement properties in different kinds of MSK pain problems.
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CHAPTER 1: Literature Review
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Overview of Musculoskeletal Disorders
‘Musculoskeletal disorders’ (MSDs), as a term, describes a vast number of
inflammatory and degenerative conditions affecting the muscles, tendons, ligaments, joints,
peripheral nerves, and supporting blood vessels (1). More than 291 pathologies (2) have been
defined as MSDs, and may include conditions with a) unambiguous pathophysiology such as,
tendon inflammations (e.g. tenosynovitis, epicondylitis, bursitis), nerve compression disorders
(e.g. carpal tunnel syndrome, sciatica), and osteoarthritis, or b) conditions with ambiguous or
less standardized pathophysiology (e.g. myalgia, low back pain) and generalized body pain of
unknown cause (1,3). MSDs predominantly affect the low back, neck, shoulder, forearm,
hand, and the lower extremity (1,4).
MSDs are the most common cause of long-term pain and disability (3,5,6). MSDs
impact negatively on an individual’s level of participation, quality of life, social,
psychological and economic well-being (6,7). The prevalence of MSDs is high and is
expected to continue to increase for several reasons including greater rates of obesity,
sedentary lifestyle, and the growing ageing population (3). MSDs currently account for 21.3%
of the total years lived with disability (YLDs) and globally represent the 4th largest health
burden (8). Prevalence rates are higher in developed countries than in developing countries.
For instance, at any one time, joint pain, swelling, or limitation of movement will affect no
less than 30% of American adults in their life time and represent the leading cause of
disability among adults within or below 45-year-old (6). In Ontario Canada, MSDs account
for 40% of all chronic conditions, 54% of all long-term disabilities and 24% of all restricted
activity days (9). MSDs such as rheumatoid arthritis, osteoarthritis, osteoporosis, spinal
disorders and major limb traumas come with the greatest financial consequence on the
individual and society (8). In Canada, treatment and management of MSDs directly accounts
for 7 billion dollars in expenditures, including cost of research, hospital bills, medical services
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and professional bills, while MSDs indirectly cost 25 billion dollars from loss to
disability/profitable work hours and premature death (7). Recent reports for the United States
indicate MSDs cost over 125 billion dollars per annum directly and indirectly. Indeed, MSDs
are pervasive burdens with influence reaching all ages, walks of life, countries and regions.
Overview of Shoulder Pain
Shoulder pain, the third most common musculoskeletal complain after back and neck
pain, originates from different problems affecting the shoulder structures (10–12). As the most
mobile joint of the body, the shoulder is at high risk of instability and pain. Also, the shoulder
links the upper extremity to the thorax; hence, tissues including muscles, tendons, and major
neurovascular structures surrounding the shoulder indirectly become potential sources of
referred pain (12). Examples of conditions affecting the shoulder directly include: (a) Rotator
Cuff Disorders (RCDs): a group of disorders including rotator cuff tendinopathy,
impingement, sub-acromial bursitis, rotator cuff tears; (b) Glenohumeral Disorders: capsulitis
(“frozen shoulder”), arthritis; (c) Acromioclavicular Diseases; (d) Infection; and (e) Traumatic
Dislocation. Of these conditions, RCDs are the most common pathology affecting the
shoulder joint. Other conditions that can affect the shoulder indirectly include: (a) Neck Pain;
(b) Myocardial Ischemia; (c) Referred Diaphragmatic Pain; (d) Polymyalgia Rheumatica; and
(e) Malignancy i.e. apical lung cancers or metastases (11).
A review of shoulder pain/complaints prevalence studies till the year 2001(13) noted
substantial variation in ranges across study reports: point prevalence ranged from 7-27%
(adults > 70 years) and 13.2 – 26% (adults < 70years). The annual prevalence of shoulder
pain/complaints ranged from 5 – 47% (13); another review estimated prevalence of shoulder
complaints at 50% in the general population (14). The annual incidence of shoulder
complaints was 7% in the general population (14) but varied across different age groups at
0.9% (31-35years), 2.5% (42-46 years), 1.1% (56-60 years), and 1.6% (70-74years) (13).
3

Leclerc et al. (15) has summarized risk factors for shoulder pain as a mix of personal
(e.g. age and gender), occupational factors (skilled, semi-skilled or unskilled jobs), lifestyle
behaviors (e.g. physical inactivity) and existing comorbidities (e.g. depression, heart and sleep
conditions, and obesity). While the risk of shoulder pain increases with age (15), being a
female (16) and having a long history of smoking are other risk factors for shoulder pain (17).
Individuals who engaged or are engaging in an unskilled job that requires the constant use of
their upper limb are more likely to report shoulder pain than those in skilled and semi-skilled
jobs who do not use their upper limb repetitively while performing their job responsibilities
(18). Physically inactive persons are also highly predisposed to shoulder pain (19). Moreover,
the presence of mental/psychological comorbidities like depression and anxiety (20),
undergoing a previous shoulder surgery, or even experiencing a past injury/dislocation on the
shoulder can increase the risk of persistent shoulder pain (15).
Musculoskeletal Pain as a Multidimensional Construct
The International Association for the Study of Pain (IASP) describes pain as: “an
unpleasant sensory and emotional experience associated with actual or potential tissue
damage, or described in terms of such damage” (21). Pain is not only the most recurrent
symptom in musculoskeletal disorders but also accounts for most of the accompanying burden
of disease (22). Although pain was initially perceived as a unidimensional construct with a
resultant emphasis on capturing intensity, overwhelming evidence has established the
multidimensional nature of pain (23,24). For instance, Melzack and Casey (25) hypothesized
three dimensions, including: the sensory–discriminative, motivational–affective and
cognitive–evaluative. The experience of pain perception is the confluence of six dimensions:
physiologic, sensory, affective, cognitive, behavioral and socio-cultural (26,27). Since pain is
multidimensional in nature, comprehensive pain assessment depends on the use of validated

4

multidimensional patient-reported outcome measures (PROMs) that can adequately capture
and quantify how pain impacts on different domains.
Patient-reported Outcome Measures (PROMs)
Patient-reported outcome measures (PROMs) are standardized, validated
questionnaires completed by patients to measure their perceptions of their own functional
status and wellbeing (28). Although initially developed for monitoring treatment effectiveness
in clinical trials, PROMs are now used to also evaluate the patients view about their
symptoms, functional status, treatment and other health-related qualities of life (28–30). In the
past two decades, the importance of PROMs has been more recognized and widely accepted
in health care practice. This is due to a shift in understanding that the patient’s perspective
about their health is genuine, and as valid as findings obtained from conventional biomedical
clinical tests, lab results, and the clinicians’ view (29,31).
Types of PROMs and their Advantages.
PROMs can be classified into seven main types (29). The first is disease-specific tools
e.g. Western Ontario Rotator Cuff index (32): they focus on a specific disease, and are likely
more sensitive to change, and appreciated by patients. Secondly, site or region-specific tools
e.g. Knee injury and Osteoarthritis Outcome Score (33) or Shoulder Pain and Disability Index
(34) can be used to evaluate conditions affecting the region of interest, often irrespective of
the origin of pathology. Third are dimension-specific tools e.g. the Brief Pain InventoryShort Form (BPI-SF) (35) or Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ2) (36): they provide the advantages of a thorough and exhaustive assessment of a health
domain and can be compared across conditions. Fourth, generic tools e.g. the Medical
Outcome Study 36-Item Short-Form Health Survey (37) can be applied in multiple conditions
when disease-specific assessments are not available for evaluation. Fifth, summary items are
brief and take less time to complete, providing a global rating of health or disability e.g. the
5

Global Rating of Change scales (38). Sixth, individualized PROMs e.g. Patient-specific
Functional scale (39): respondents using this tool are not bounded to questions but are free to
define their concerns or goals for treatment. Seventh, utility tools e.g. EuroQoL EQ-5D (40),
allow respondents to quantify their preferences and values regarding their overall health
status.
Psychometric Properties to consider when selecting PROMs.
Many outcome tools can be used for pain assessment in musculoskeletal conditions
and selecting the most appropriate outcome measures for clinical or research purposes has
become a difficult task that requires good understanding of psychometric properties, in
addition to other factors (29,41,42). Some of the important psychometric properties that need
to be considered when making decisions to select a PROM includes:
1.

Validity, the level to which a tool measures the intended construct(s) (29,43), should

be satisfactorily established for a tool to be considered for evaluation purposes. Ways of
estimating validity includes investigating: (a) convergent and discriminative validity, where a
clear hypothesis must be provided a priori (44,45); (b) criterion validity, where comparison is
made against an established gold standard (42,46); and (c) structural validity using Rasch
modelling or factor analysis to examine the dimensionality of multidimensional tools (41,42).
Content validity is the most foundational type of validity since without it, other
validity indices have little value. It is the degree to which the content of a PROM instrument
reflects the construct to be measured (43) and as such, describes how representative the items
of a PROM reflect the patient’s perspective under evaluation. Face validity can also be
evaluated as a step toward establishing content validity. It entails synthesizing the impression
of experts and/or patients (tool users) on the adequacy of tool (41,47). An instrument’s
content must adequately reflect what it is expected to evaluate before it should be considered
for use (47). This benchmark must be established before any further investigation of
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psychometric properties because a tool with unrepresentative items does not merit any further
evaluation (29,47).
2.

Reliability, the degree to which the measurement is free from error (43), describes the

reproducibility and internal consistency of a PROM instrument. Reproducibility is a critical
measurement property that needs to be determined, especially, for all pain assessment tools. It
measures the degree to which repeated measurements in stable respondents provide similar
results (48–50) and as such, precedes evaluation of responsiveness or validity. Good evidence
demonstrating relative and absolute reliability of a tool supports reproducibility; however,
both forms of reliability focus on two different questions (48,51,52).
Absolute reliability (agreement) examines how closely related the scores from
repeated measurement are comparable - that is, the more closely related, the higher the
reliability, which substantiates the evaluative ability a tool. Methods examining standard error
of the measurement (SEM) and minimal detectable change (MDC), and inspecting the
distribution of scores on Bland-Altman plots provide evidence in support of a tool’s absolute
reliability (48,49). On the other hand, relative reliability is the degree to which individuals
maintain their position in a sample over repeated measurements (48,49,51). The intraclass
correlation coefficient (a unitless measure with magnitude ranging from 0 (poor) to 1 (very
good) is the most accepted means of measuring relative reliability for ratio or interval scale
scores. Higher ICC scores support the ability of a tool to discriminate between subjects
regardless of measurement error (51,53,54).
Test-retest reliability is assessed by testing participants on repeated occasions (55).
The PROM should be administered repeatedly within in a short enough time interval that
ensures patients stability yet long enough time interval that avoids learning or memory effects.
Internal consistency, measured using Cronbach’s alpha, is a weaker form of assessment that is
commonly used to determine the degree of the interrelatedness among items (56,57).
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3.

Responsiveness, the ability of a PROM to evaluate change over time in the construct

to be measured (43), refers to an instruments ability to detect clinically relevant change.
Evaluative instruments, like pain assessment tools, are expected to be able to determine the
presence or absence of change in status following intervention. Some of the acceptable
statistical approaches utilized for determining a tool’s level of responsiveness include: (a)
calculating the area under the curve (AUC) using the Receiver Operator Curve (ROC curve),
(b) estimating the standardize response mean (SRM) or effect sizes and, (c) estimating the
level of correlation with similar outcomes (44,58). Well-defined hypotheses with magnitude
and direction of change should always be provided while considering the expected effect of
administering or withholding an intervention (44,45,59). Statistical methods like the use of the
paired T-test for significant differences between groups or Guyatt’s responsiveness ratio (60)
should not be used as indicators of responsiveness (58).
4.

Interpretability, the degree to which one can assign qualitative meaning—that is,

clinical or commonly understood connotations—to an instrument's quantitative scores or
change in scores (43), is often established by estimating the minimal clinically important
difference (MCID) score of the tool. Interpretability makes an instrument easy to use and
understand in clinical practice and assists with classification and prediction.
Systematic Reviews of Measurement Studies
Systematic reviews of measurement studies involve identifying, extracting, critically
appraising and comparing ‘contextual’ evidence from the literature on a tool’s measurement
properties (61). Evidence from systematic reviews informs decisions made for or against a
tool and instill user’s confidence in the tool’s performance. Robust systematic reviews of
measurement studies rely heavily on critical appraisals to authenticate and synthesize the
quality of evidence supporting PROMs measurement properties. Critical appraisals often
involve examining the quality of the measurement evidence (i.e. validity, reliability,
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responsiveness, etc.) against established standards, and evaluating the methodological quality
of the study for bias (risk of bias). In some critical appraisal tools, the feasibility/usability of a
tool, the administration burden and response burden are examined as part of the appraisal
process. Two popular critical appraisal tools used in measurement studies are: (a) The
(COnsensus-based Standards for the selection of health status Measurement INstruments)
(COSMIN) Methodology, which comprises the risk of bias (44,45), quality citeria checklist
(44,46,49) and the modified Grading of Recommendations Assessment, Development and
Evaluation (GRADE) (44) and, (b) MacDermid’s measurement studies quality assessment
checklist (41). While complimentary, they have individual strengths and weakness which need
to be appreciated.
Strengths and Limitations of the COSMIN Methodology
One of the main advantages of the COSMIN methodology lies in its standardized
definition of measurement properties which guarantees less confusion when extracting
evidence as described by reporting authors. Also, the COSMIN examines risk of bias per
report of measurement properties. Therefore, a poor outcome for reporting of one
measurement property does not necessarily impact on the rating of other reports in the same
article because each report is treated as a ‘stand-alone’ study. Finally, a comprehensive user’s
manual (44) is available for reviewers to consult which decreases subjectivity. However, one
disadvantage of the COSMIN method is that inexperienced users will find it difficult and
confusing to synthesize and complete all stages of the critical appraisal involving completing
the risk of bias, quality criteria checklist and Modified GRADE level of evidence
determination. Further, some of the criterion are quite arbitrary: for instance, a sample of 50100 subjects is needed for a study to be rated adequate in reliability assessment, even though
sample size calculations often suggest less. Arbitrary benchmarks or items that affect
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imprecision are also included as bias criterion. This can have a major impact since it is the
lowest rating in a section that is selected as the overall rating.
Strengths and Limitations of the MacDermid’s Appraisal Method
MacDermid’s tool is focused on overall study design and quality, not the bias
associated with individual measurement properties. The scaling is numbered, and a total sum
can be generated which makes it easy for users to conclude on the quality of studies. This
attribute allows for identification of common design flaws in the individual studies. However,
the weight apportioned to quality indicators is arbitrary and does not necessarily reflect the
impact of potential sources of bias. Further, the focus on study design, rather than individual
measurement properties, does not directly align with the information needed to make
decisions about the adequacy of individual measurement properties. In addition, more training
may be required to resolve complexity or sources of disagreement between raters from the
absence of standardized definitions of measurement properties. As a quality tool, it does not
focus on assessing risk of bias. Quality and risk of bias are related but separate constructs.
The Brief Pain Inventory-Short Form (BPI-SF): History, Content Structure and
Advantages
The Brief Pain Inventory, formerly the Wisconsin Brief Pain Questionnaire (62,63),
was initially developed to provide a simple but comprehensive outcome tool for monitoring
analgesic effect in cancer pain management, epidemiological studies and research. Early
versions were developed with sponsorship of the National Cancer Institute (NCI) and the
Cancer Unit of the World Health Organization (WHO) (63). The Brief Pain Inventory has
undergone series of transformations to improve its structure, including, the addition of the
‘least pain item’, and reducing the number of items in its long version - to decrease
responders’ burden (63). While the long version is still used for clinical research purpose, the
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short version, commonly referred to as the Brief Pain Inventory, is employed for pain
assessment in conditions including musculoskeletal disorders (63).
The content structure of the BPI-SF is based on Beecher’s definition of pain
dimensionality as ‘sensory’ and ‘reactive’(64). The sensory dimension of the tool evaluates
how pain severity/intensity fluctuates on four items: pain at its - ‘worst’, ‘least’, ‘on average’
and ‘now’. The reactive dimension of the tool evaluates how responders perceive pain
interference in two sub-dimensions: (a) an activity sub-dimension consisting of 3 items:
‘work’, ‘general activity’ and ‘walking’, and (b) an affective sub-dimension consisting of 3
items: ‘relations with others’, ‘enjoyment of life’, and ‘mood’. One item, ‘pain interference
with sleep’, stands alone and can be influenced by both sub-dimensions (63).
As the name suggests, the greatest advantage/strength of the BPI-SF is its simplicity
and brevity: it takes 5-minutes to complete, yet it captures pain comprehensively. Also, the
BPI-SF evaluates pain ‘interference’, uniquely, with items easily appreciated by patients:
hence, the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) group has recommended its use in all chronic pain-related clinical trials (65).
Finally, multiple language translations (63), based on standard translation processes, are
available for the BPI-SF which encourages its global use.
The Revised Short McGill Pain Questionnaire-2 (SF-MPQ-2): History, Content
Structure and Advantages
The Revised Short McGill Pain Questionnaire Version-2 was developed about a
decade ago (1st January, 2019) after Dworkin and his team noted the absence of a single tool
for neuropathic and non-neuropathic pain assessment (36). The previous Short McGill Pain
Questionnaire was then expanded to the current Revised Short McGill Pain Questionnaire
Version-2, to be able to simultaneously evaluate and/or discriminate neuropathic and nonneuropathic pain symptoms.

11

The content structure of the expanded SF-MPQ-2 consist of 22 items: 15 items of
which were retained from the former version, the Short McGill Pain Questionnaire (36). The 7
new items added comprise the neuropathic subscale and were selected based on the
researchers experience and the results of focus groups with chronic pain patients (36). The SFMPQ-2 evaluates 2 dimensions of pain: (a) sensory (pain quality and intensity) and, (b) an
affective dimension (emotional experience of pain). Aside its evaluative properties, it has a
high discriminative property to distinguish different pain types/qualities. Its 22-items
distinguish pain into 4 categories: (a) continuous (throbbing pain, cramping pain, gnawing
pain, aching pain, heavy pain, and tender); (b) neuropathic (hot-burning pain, cold-freezing
pain, pain caused by light touch, itching, tingling or pins and needles, and numbness); (c)
affective (tiring-exhausting, sickening, fearful, punishing-cruel), and (d) intermittent (shooting
pain, stabbing pain, sharp pain, splitting pain, electric-shock pain, piercing).
As its strengths, the SF-MPQ-2 does not only assess pain intensity but can also be
used to distinguish pain according to its source. This makes it very useful for pain assessment
when there is need to be sure of the mechanism of pain (nociceptive or neuropathic), or when
there is need to quantify mixed (both neuropathic and nociceptive) pain experiences. On the
down side, some of the SF-MPQ-2 pain descriptors are difficult to appreciate by patients
(66,67). Also, 22 items in one questionnaire may be perceived as too long and burdensome to
complete (66,67). Finally, although the Mapi Research Trust has provided computerized
translations of the SF-MPQ-2, they are not based on standardized cross-cultural translations
involving forward and backward translation processes.
Current Gap in the Literature

The main objective of this thesis was to explain the sufficiency of measurement
evidence backing the use of the Brief Pain Inventory- Short Form and Revised Short McGill
Pain Questionnaire Version-2 in pain-related musculoskeletal conditions. Currently, both tools
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are used frequently for musculoskeletal pain assessment both in the clinical and research
setting, however, no single study has synthesized the scope of evidence supporting their
measurement properties for use in MSK conditions. MSK conditions are common but diverse.
Clearly understanding the measurement properties backing outcome measures can inform
users choice. Hence, the absence of a comprehensive review of the evidence suggest selection
by researchers/clinicians is based on reports obtained from single studies, colleagues or peers’
recommendations, easy access to the tools, high recognition or even the appearance of their
items/face validity (68). However, we know that comprehensive pain assessment depends on
the use of tools with proven context-specific evidence backing their measurement properties,
because only valid tools yield dependable scores (41,42,44–46,59,69). Therefore,
systematically reviewing the literature to determine the sufficiency of evidence for
measurement properties underpinning the use of the BPI-SF and SF-MPQ-2 in MSK
conditions is overdue and necessary.

The two research questions guiding this dissertation were as follows:

1. What is the quality and content of measurement evidence supporting the use of the
Brief Pain Inventory-Short Form and Revised Short McGill Pain Questionnaire
Version-2 in Musculoskeletal Conditions?
2. What is the reproducibility (reliability and agreement parameters) and internal
consistency of the Revised Short McGill Pain Questionnaire Version-2 for use among
patients with musculoskeletal shoulder pain?
Composition of Dissertation Papers

This dissertation consists of two papers presented in a manuscript style as Chapters
two and three. Chapter two is a systematic review manuscript. Chapter three is a research
study on the reproducibility of the Revised Short McGill Pain Questionnaire Version-2 among
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patients with shoulder pain. The systematic review (Chapter – 2) examined the quality and
content of measurement evidence reported for the Brief Pain Inventory-Short Form and
Revised Short McGill Pain Questionnaire Version-2 in pain-related musculoskeletal
conditions. In this review, we synthesized, appraised and compared reported evidence on the
measurement properties of both outcome tools. The critical appraisal involved two methods
that checked the quality and risk of bias (the COSMIN guidelines) and the rigor of authors
report of measurement properties (MacDermid’s tools). The review findings helped us
identify the gaps in the literature which informed our objective in the third chapter of the
dissertation.

The third chapter of the thesis comprehensively examined the reliability and
agreement properties of the Revised Short McGill Pain Questionnaire Version-2 among
patients with musculoskeletal shoulder pain. In this study, the internal consistency, test-retest
reliability, standard error of measurement (SEM), minimal detectable change (MDC) and
Bland-Altman methods were used to assess the reproducibility of the SF-MPQ-2. The results
of the study established evidence in support of the reproducibility of the SF-MPQ-2 for use
among adults with shoulder pain. In summary, research in this thesis attempts to address the
literature gaps in measurement evidence by systematically summarizing the available
evidence on the psychometric properties of the Brief Pain Inventory-Short Form and Revised
Short McGill Pain Questionnaire Version-2 and evaluating the reproducibility of Revised
Short McGill Pain Questionnaire Version-2 among patients with musculoskeletal shoulder
pain.
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ABSTRACT
Study design: Systematic review of clinical measurement studies.
Background: The BPI-SF and SF-MPQ-2 are general-use, self-report, multidimensional pain
measures frequently used in musculoskeletal (MSK) conditions. Synthesizing knowledge of
their measurement properties, as assessed in MSK conditions, should provide a deeper
understanding of their strengths and limitations.
Objectives: To systematically locate, critically appraise, compare and summarize clinical
measurement research addressing the use of BPI-SF and SF-MPQ-2 in pain-related
musculoskeletal conditions.
Methods: Four databases (Medline, CINAHL, EMBASE & SCOPUS) were systematically
searched for relevant citations, each for the BPI-SF and SF-MPQ-2. We included articles
reporting the psychometric properties (e.g. validity, reliability, responsiveness) and
interpretability indices (e.g. minimal clinically important difference) of both tools, as assessed
in mixed and specific MSK studies. Independently, two reviewers extracted data and assessed
the quality of evidence with the MacDermid’s measurement studies quality assessment tool
and the updated COnsensus-based Standards for the selection of health Measurement
INstruments (COSMIN) guidelines.
Results: Twenty-five articles were included (BPI-SF, n=17; SF-MPQ-2, n=8). Both tools lack
reporting on their cross-cultural validities and measurement error indices (standard error of
measurement, minimal detectable change). High quality studies suggest the tools are
internally consistent (α = 0.83-0.96), and they associate modestly with similar outcome
measures (r = 0.3-0.69). There is strong evidence suggesting the BPI-SF conforms to its twodimensional structure in MSK studies; the SF-MPQ-2 four-factor structure was not clearly
established. Seven reports of high-to-moderate quality evidence were supportive of the BPISF known group validity (n=2) and responsiveness (n=5) while no similar evidence was
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available for the SF-MPQ-2. Furthermore, the SF-MPQ-2 was more frequently associated
with floor effects in MSK studies than the BPI-SF (SF-MPQ-2, 42% vs BPI-SF, 6%).
Conclusion: Although the SF-MPQ-2 presents potential, and both tools display high-quality
evidence in support of their internal consistency and criterion-convergent validities, high to
moderate quality evidence suggests the BPI-SF subscales have a better responsiveness, retest
reliability, known group validity and structural validity than the SF-MPQ-2. Therefore, the
BPI-SF is currently better for pain assessment in MSK conditions. However,
methodologically sound studies are still needed for both tools’ measurement properties
including their cross-cultural validities, retest reliability, measurement error indices, minimal
clinical important difference and clinical important difference.
Keywords: Brief Pain Inventory; McGill Pain Questionnaire; Musculoskeletal Conditions;
Patient-Reported Outcome Measures; Psychometric Properties
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INTRODUCTION
Musculoskeletal (MSK) conditions are among the leading causes of years lived with
disability.15,53 Pain originating from MSK conditions has a significant impact on patients’
general wellbeing and commonly results in frequent visits to the emergency or outpatient
department of hospitals and clinics.3,22 Patient-reported outcome measures (PROMs) are the
primary methods of assessing and monitoring the patients’ pain experience, and well validated
PROMs help clinicians make informed care decisions.27,30,44 A large number of PROMs with
multidimensional scales now exist for pain assessment in various conditions including MSK
disorders. The Brief Pain Inventory-Short Form (BPI-SF)8 and the Revised Short McGill Pain
Questionnaire Version-2 (SF-MPQ-2)10 are examples of generic PROMs that are increasingly
being used for pain assessment in musculoskeletal conditions: experts are currently presenting
these tools as core outcomes for pain assessment in chronic musculoskeletal pain studies
(BPI-SF)9,23 and complex regional pain syndrome (SF-MPQ-2 neuropathic subscale).13
The BPI-SF contains 11-items evaluating the severity and interference of pain with
daily functioning. Four items quantify patients’ responses on the severity of pain at its ‘worst’,
‘least’, ‘on average’ and ‘now.’ Each of the four descriptors are anchored to a common
scaling structure that has zero as ‘no pain’ and 10 as ‘pain as bad as you can imagine’. To
obtain a total pain-severity score, the mean of the 4 severity items is computed. The
interference subscale of the BPI-SF captures the patients’ perception of how pain impacts
seven constructs: ‘mood’, ‘enjoyment of life’, ‘relationship with others’, ‘sleep’, ‘general
activity’, ‘walking ability’, and ‘work’. Each of the seven items are equidistantly bounded on
a zero-to-10 numerical rating scale having zero as ‘does not interfere’ and 10 as ‘completely
interferes’. To obtain a total pain interference score, the mean of four or more of the
interference items must be computed.7
The Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2)10 was created
by expanding its parent version, the Short McGill Pain Questionnaire (SF-MPQ). It
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concurrently evaluates the severity and characteristics/qualities of pain originating from both
neuropathic and nociceptive sources. The SF-MPQ-2 has 22-items evaluating pain across four
dimensions as follows: 1) continuous pain (throbbing, cramping, gnawing, aching, heavy, and
tender pain); 2) intermittent pain (shooting, stabbing, sharp pain, splitting pain, electric-shock,
and piercing pain); 3) neuropathic pain (hot-burning, cold-freezing, pain caused by light
touch, itching, tingling or pins and needles, and numbness pain), and 4) affective pain (tiringexhausting, sickening, fearful, and punishing-cruel). Each pain descriptor is scored on a zero
(none)-to-10 (worst possible) numerical rating scale. The total pain score is the mean of the
22-items, while the total subscale scores are the mean of each of their respective descriptor
cluster.10
Like some generic tools, the BPI-SF and SF-MPQ-2 were originally developed and
tested for pain assessment in specific-disease populations. For instance, the BPI-SF was
originally developed for cancer pain assessment8,20 while the SF-MPQ-2 was purposefully
expanded to include the neuropathic pain elements, and initially validated in a diverse chronic
pain population with patients having conditions including neck and shoulder pain, and painful
diabetic neuropathy.10 Currently, however, both tools are deemed useful for pain assessment
in other conditions, including musculoskeletal conditions. Although evidence supporting the
measurement properties of both tools has continued to accumulate, there has been no
systematic inquiry on their performance as ‘general-use’ pain assessment tools in
musculoskeletal conditions. Previous reviews of the BPI-SF5,6,43 and the SF MPQ-243 only
summarized their measurement properties as examined in back pain, with no report on other
MSK conditions.
However, by systematically extracting evidence from the pool of studies that have
reported the BPI-SF and SF-MPQ-2 measurement properties in mixed and specific MSK
populations, we expect to have a broader understanding of their measurement performance in
MSK conditions. Such knowledge aids decision-making in the clinical and research setting,
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and helps in selecting the appropriate outcome measure for use, for example, in
epidemiological pain studies where these tools are sometimes employed.11 Furthermore, the
methodological quality of a study places value on its report of measurement properties:
therefore, a thorough critical appraisal of the measurement reports would help identify their
risk of bias, which often modifies the strength accorded the studies’ conclusions.36
Investigating the two questionnaires measurement properties is timely and will yield
insights on how they efficiently assess pain in MSK conditions. Such knowledge can guide
the preferences of the busy clinician/researcher encountering such conditions thus fostering
evidence-based practice in MSK pain management. The objective of this review was to
systematically locate, summarize, critically appraise, and compare the quality of measurement
research utilizing the Brief Pain Inventory-Short form (BPI-SF) and the Revised Short McGill
Pain Questionnaire Version-2 (SF-MPQ-2) in pain-related musculoskeletal conditions.
METHODS
Design
This review followed the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement and checklist,35 and the protocol manuscript16 was registered
with Prospero (CRD42018095862). The review was conducted in four steps: (a)
comprehensive searches were performed in four bibliographic databases to identify relevant
citations, each for the BPI-SF and SF-MPQ-2; (b) title, abstract and full-text were screened to
fit pre-determined standards; (c) data on measurement properties were extracted; (d) in two
phases, the MacDermid’s measurement studies quality assessment tool and the COSMIN
guidelines were used to assess the quality of the included studies.
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Data Source and Search Strategy
Search strategies developed in consultation with a health-research librarian were run
last on the 10th of July 2019 in the Medline—OVID, EMBASE—OVID, CINAHL
(Cumulative Index to Nursing and Allied Health Literature), and Scopus bibliographic
databases to identify relevant citations. The search concepts for measurement properties were
refined from a previous comprehensive search filter validated by Terwee et al50 and included
different measurement property keywords (see Appendix 1). The search for studies
addressing the BPI-SF properties was not restricted by time or language. However, the search
for the SF-MPQ-2 articles was restricted by time to its year of first publication (i.e. January
1st, 2009)10 in order to limit citations related to its parent versions (SF-MPQ and MPQ) but
language was not restricted.
Eligibility requirements
Inclusion Criteria:
(i) We included only studies whose purpose was to evaluate at least one of the measurement
properties of the BPI-SF and SF-MPQ-2 in a sample population characterized with MSK
conditions fully, or to an extent that satisfies 70-percent of the study sample size.
(ii) We included studies with available full text, published in a peer-reviewed journal in any
language and conducted in a population within the age of 16 years and above.
Exclusion Criteria:
(i) We excluded all letters to the editor, review articles, book reviews and short
communications, clinical protocols, case reports, animal studies, and series.
(ii) We excluded studies without explicit evidence that describe pain to be of MSK origins
either in summary tables or text. Examples of such articles include studies with unclear terms
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used to define the sample populations’ pain, such as, ‘non-malignant pain’ or ‘chronic pain’ or
‘non-cancer pain’ without clearly relating such pain to be of MSK origin fully, or partly.
(iii) We excluded studies conducted in disability or pain-related conditions that were primarily
due to some of the following: congenital and developmental abnormalities, neoplasm,
infection, surgical procedures not due to MSK conditions (e.g. coronary heart surgery,
laparotomy), neurological or neuropathic pain (undefined as lumbar, cervical or thoracic
radiculopathies with back pain), or HIV/AIDS pain.
Study selection and screening
Prior to the screening/selection phases, articles retrieved from each database were
exported to the Covidence systematic review software (Veritas Health Innovation, Melbourne,
Australia - available at www.covidence.org), for de-duplication and study selection. In line
with the eligibility requirements, the screening/selection took place in two steps: first, title and
abstracts were independently screened for obviously unrelated articles. We then assessed the
full text of emerging articles for congruency with the aims and eligibility requirements of the
review. A further hand search of the included studies reference list was conducted, each for
the BPI-SF and SF-MPQ-2, to identify any other relevant citations. All disagreement during
the selection were discussed and settled among the screening authors (JS and MK).
Data extraction
We extracted data from individual studies using a structured data extraction form
developed from the guide available in the second author’s (JCM) work.28 Two review authors
(JS and MK) worked independently to extract data from the included studies, and a third
review author was to be contacted if any disagreement arose. When reported, the following
information were extracted: floor-ceiling effect, construct validity (criterion-convergent and
known group), internal structure (internal consistency and structural validity [i.e. Rasch and
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factor analysis]), reliability (test-retest), responsiveness (AUC’s, change correlation indices,
standardized response mean [SRM], effect-size [ES]), interpretability properties (clinically
important difference [CID], minimal clinically important difference [MCID]), measurement
error indices, and measurement invariance/cross-cultural validities. Data was summarized
according to the subscale of the tools evaluated. To guide our review, painful MSK conditions
were defined as disorders affecting the muscles, bones, soft tissue, joints and spine.40 We then
classified the acceptable studies into populations as follows:
a) ‘Mixed’ MSK population studies: studies that satisfied the requirements of ≥ 70-percent
sample size proportion representing MSK conditions of different mechanism or
pathophysiology or described by different body regions.
b) ‘Specific’ MSK population studies: those conducted among homogenous MSK samples
described by the body region affected or the pathophysiology/mechanism.
We also extracted information on: (a) the characteristics of the studies, for example,
country where the study was conducted, language, study design, study setting, the SF-MPQ-2
and BPI-SF language/version/subscale/item used, and (b) participants characteristics including
sample size, age, and sex.
Review Team Hypotheses
The following hypotheses, as suggested by the COSMIN36,38 initiative, were defined in
advance by the review team to guide the quality assessment phase.
a) Correlations between the two questionnaires and other pain/health-related outcome tools
were expected to be 0.3 and above in magnitude. Correlations were then classified as low to
moderate at 0.3-0.69; high at 0.7 and above.28,32
b) The lower bound confidence intervals of reports supporting Area Under the Curve (AUC)
estimates had to be ≥ 0.7 to represent discrimination beyond chance.
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c) We described the correlation indices between the change scores of other pain/health-related
outcome measures and the two questionnaires as sufficient at ≥ 0.3.
However, the review team could not define hypotheses to assess authors
responsiveness report based on the standardized response mean (SRM) and effect size (ES)
indices. As such, article authors were expected to provide context-specific hypotheses that
defined the magnitude and direction of expected change.
Quality Assessment
Quality assessment was conducted in two phases: first, the MacDermid’s measurement
studies quality assessment tool26 was used to appraise the included studies. Next, the
COSMIN guidelines36,41,42,49 were used to examine methodological risk of bias and to
compare reported measurement properties against benchmark quality standards. Both phases
of quality assessment were deemed complementary.
Phase 1: Quality, Comprehensiveness and Breadth of Measurement Evidence Reports
An initial calibration meeting informed the reviewers’ (JS and MK) independent
appraisal of the included articles. MacDermid’s measurement studies quality assessment tool26
was used to examine the quality, breadth and rigor of authors report against 12 criteria. Where
applicable, each criterion receives: 0-points, if judged, ‘not done/documented’ OR ‘substantial
inadequate’ OR ‘inappropriate’; 1-point, if judged, ‘acceptable but suboptimal’; and 2-points,
if judged, ‘consistent with best practice’, and NA if judged ‘Not Applicable’ to a study. An
article can receive a total score ranging from zero (lowest) to 24 (highest) points, which can
be converted to a percentage that represents its total quality rating. Percentile scores were
interpreted as follows: poor quality report, 0%–30%; Fair, 31%–50%; Good, 51%–70%; Very
good, 71%–90%; Excellent, >90%. The reliability of the process was calculated.
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Phase 2: Risk of Bias Assessment and Quality of Measurement Properties
In this phase, the same review authors (JS and MK) independently assessed the
included studies for conformity with the COSMIN risk of bias (RoB)38,41 and quality criteria
checklists.42,49 The RoB checklist consists of 10 boxes, each representing a measurement
property featured in the COSMIN consensus-based taxonomy.37 Irrespective of the
terminology used to define measurement properties by individual authors, we defined all
measurement properties according to the COSMIN consensus-based taxonomy of
measurement properties,37 and that determined the corresponding box to complete for the risk
of bias assessment. Each of the risk of bias assessment box contains several items/questions
that are scored on a 4-point rating scale as ‘very good’, ‘adequate’, ‘doubtful’ and
‘inadequate’.38 The lowest rating for any item/question on a study’s measurement property
determines its overall rating for methodological risk of bias based on the worst score count
system. Of the ten boxes in the COSMIN risk of bias checklist, we ignored two boxes: PROM
development and content validity, because the BPI-SF and SF-MPQ-2 were not initially
validated in study populations satisfying our inclusion criteria.36,38
In the second phase of the COSMIN quality assessment, all the extracted data on
measurement properties for each of the tools were rated against the good measurement
property quality criteria, as available in the COSMIN User’s Manual Version-1.36,42,49 Based
on the category of the measurement property reported (e.g. internal consistency, test-retest
reliability), studies were compared and rated against the COSMIN quality criteria as:
‘Sufficient’ (+), if within the benchmark quality criteria; ‘Indeterminate’ (?), if there was an
inadequate report to compare to the benchmark quality criteria, and; ‘Insufficient’ (-), if the
reported measurement property was below the benchmark quality criteria.
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Evidence Synthesis
To determine the level of evidence supporting the two questionnaires measurement
properties, we applied the Modified GRADE (Grades of Recommendation, Assessment,
Development, and Evaluation) as described by the COSMIN initiative.36 In our synthesis,
more attention was given to the consistency of reports contained in studies with ‘sufficient’
(+) quality ratings (which is the acceptable quality criteria rating) and prone to lesser risk of
bias: that is, with ‘very good’ or ‘adequate’ risk of bias rating. First, we pooled/summarized
the results extracted on each measurement property, per tool. For example, the estimated
intraclass correlation coefficient (ICC) for the BPI-SF and SF-MPQ-2 was summarized using
a weighted average. Cronbach alpha for internal consistency was summarized using the
observed range of occurrences across the studies with a low risk of bias. Proportions were
used to summarize the number of correlations within the low-to-moderate range (rho = 0.30.69), and ‘high’ range (rho ≥ 0.7). For structural validity, responsiveness and known group
validity, we considered the number of studies with a low risk of bias rating available on each
of those measurement properties, per tool, and used narrative synthesis to summarize their
findings. Conclusions were formulated using the Modified GRADE level of evidence
approach while considering the risk of bias, inconsistency, imprecision and indirectness of the
pooled results, under the assumption that all the captured conditions were MSK conditions,
regardless of their type (mixed or specific).38,41 The same pair of reviewer (JS and MK)
conducted both phases of the quality assessments and synthesis, independently, in line with
the review teams hypotheses. The review authors met and discussed their ratings until
consensus was reached. No further clarification was needed from a third author.
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RESULTS
Figure 1 summarizes the review screening and selection processes. Our searches
identified 1267 unique citations after de-duplication. We reviewed 92 articles in full text after
the title and abstract screening phase. In total, 25 articles satisfied the review teams
criteria.1,4,11,12,14,17–22,24,25,29,31,33,39,45–48,51,52,54,55 Seventeen (17) articles assessed the BPI-SF in
16 studies, while 8-articles evaluated the SF-MPQ-2 in 7-studies. Each of the tools had two
articles (BPI-SF21,22 and SF-MPQ-211,51) that reported from one study population and their
results were merged in this review. Some studies only focused on a particular subscale of the
BPI-SF,12,31,55 or did not assess the BPI-SF as a primary outcome,14,19,21,45 whereas all the SFMPQ-2 subscales were always examined as primary outcomes aside one that assessed only the
neuropathic subscale.39
The characteristics of the MSK populations assessed in the included studies are
summarized in Table 1. Eight studies evaluated different measurement properties of the BPISF4,12,19,21,22,24,47,48 in Mixed-MSK population studies; three examined the SF-MPQ-2.1,25,29
One or more measurement properties of the BPI-SF were assessed in Specific-MSK
population studies with conditions including fibromyalgia,31 back pain,20,46,54 knee pain,45 hip
pain,18 osteoporosis,14 and arthritis20,33,55 while subscales of SF-MPQ-2 were examined among
knee pain,29,52 complex regional pain syndrome (CRPS),39 and acute back pain11,51 patients.
Although a wide range of measurement properties were assessed for both tools, studies
reporting measurement error indices (MDC and SEM), cross-cultural validities, and
interpretability properties (CID and MCID) were scarce.
Quality of the Included Studies
All the included studies were first inspected with MacDermid’s quality assessment
tool and Table 2 summarizes the total quality score of each article. The BPI-SF articles
received quality ratings within 50% to 86%, with a mean of 67% whereas the SF-MPQ-2
displayed higher quality ratings within 63% to 92% (mean 78%). This difference in quality
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rating in favor of the SF-MPQ-2 was not surprising because it was consistently assessed as a
primary outcome in the included studies. The BPI-SF, however, was often utilized as a
comparator or secondary outcome in 4 (23%) of the included studies14,19,45,54 which impacted
negatively on its mean quality rating for some criteria assessed with the MacDermid’s quality
assessment tool.
However, some quality issues were common to both tools: a) the absence of samplesize calculation or rationalization, b) imprecise or unclear hypotheses, c) limited or
insufficient description of test procedures to an extent that allows replication of methods, d)
absence or minimal reporting of error estimates (confidence intervals, SEM), and e); overexaggerated or out-of-context conclusions/recommendations (see Table 2). Raters’ agreement
was excellent, as indicated by a high inter-rater reliability for the summary of their quality
rating scores (ICC 0.87; 95% CI, 0.79–0.92) and unweighted kappa for individual item scores
(0.75). All disagreements between the raters at this phase were clarified by the second author
(JCM).
The results of the second phase of the quality assessment according to the COSMIN
guidelines are summarized in the subsequent headings below, alongside evidence on the
extracted measurement properties. Tables 3 to 5 contain details on the BPI-SF measurement
properties, the MSK population they represent, and their quality rating as assessed, first, with
the COSMIN risk of bias (RoB), then, as benchmarked against the COSMIN quality criteria.
Table 6 summarizes the same details for the SF-MPQ-2. Finally, Table 7 summarizes the
result of the level of evidence synthesis for both tools, as per the modified GRADE.
Floor /Ceiling Effects, MCID and CID
Floor/ceiling effects occurs when a significant number of responders select scores that
concentrate at the lowest (floor) and on the highest (ceiling) limits of a PROM.49 When
compared to the BPI-SF, subscales of the SF-MPQ-2 were more frequently associated with
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floor effects in studies assessing MSK conditions. Only Kapstad and colleaques18 found
significant flooring on the BPI-SF severity [21%] and interference [28%] subscales among
total hip replacement patients 1 year post-op (Table 4). In contrast, three studies1,11,25 reported
flooring on the SF-MPQ-2 subscales: Lovejoy et al.25 found significant flooring in a ‘mixed’
study population on the affective (28%), intermittent (15.1%) and neuropathic (12.4%)
subscales of SF-MPQ-2; Adelmanesh et al1 reported less significant floor effects (3.5-8.7%)
while Dworkin et al.11 noted some floor effects on the affective subscale (15%) among
patients with acute back pain (Table 6).
Only one well-powered study (n= 1411)31 reported MCID and CID within 2.09-2.89
for the BPI-SF severity and average pain item among fibromyalgia patients (Table 4). No
study has investigated the MCID or CID of the SF-MPQ-2.
Test-retest reliability
Few studies have examined the retest reliability of the BPI-SF and SF-MPQ-2 in MSK
conditions. Three studies assessed the BPI-SF, but pooled evidence from two studies4,55
displayed a high level of evidence supporting the interference subscale retest-reliability; the
weighted ICC was ‘sufficient’ at 0.83. One report4 of ‘adequate’ RoB rating was available in
support of BPI-SF severity subscale retest reliability (ICC, 0.83) but further assessment with
the modified GRADE suggest it represents a low level of evidence due to its low sample size
(n=71) and RoB rating (Table 3). One study was rated ‘doubtful’ on the BPI-SF because the
stability of patients was not certain.33 Four studies examined the SF-MPQ-2 retest reliability:
only one17 received an ‘adequate’ RoB ratings, with ICC scores within 0.73-0.90 but
represented a low level of evidence on the COSMIN Modified GRADE due to its small
sample size (Table 6 & 7). The remaining three studies1,29,52 were rated ‘doubtful’ because of
uncertainties pertaining to patients stability; for instance, inappropriate retest intervals that
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were long enough for change to occur (3 months)52 or short enough (7-hours) to allow recall
bias1 were reported (Table 6).
In conclusion, although not consistent across all its subscales, the COSMIN modified
GRADE suggests a ‘moderate’ level of evidence of ‘sufficient’ quality currently supports the
BPI-SF retest reliability which is relatively stronger than the evidence for the SF-MPQ-2, with
‘very low’ level of evidence of ‘insufficient’ quality.
Internal consistency
Internal consistency was the most frequently reported form of reliability among the
reviewed articles, and a high level of evidence supports both tools internal consistency in
MSK studies. For the BPI-SF, eight studies with low RoB ratings (7 = ‘very good’; 1 =
‘adequate’)4,12,18,20,33,48,55 reported Cronbach alpha within 0.82 - 0.96 (Table 3). Of the five
studies that examined the SF-MPQ-2, four11,17,25,29 had ‘very good’ ratings for RoB, with
Cronbach alpha within 0.88-0.96 (total score), and 0.75-0.92 (subscales scores). The only
inadequate study failed to confirm the dimensionality of a translated version of the SF-MPQ-2
before reporting Cronbach alpha for the total scale score1 (Table 6). In summary, the
COSMIN Modified GRADE suggest a ‘high’ level of evidence of ‘sufficient’ quality supports
both tools internal consistency in MSK conditions.
Structural Validity (hypothesis testing)
Studies have addressed questions on the multidimensional structure of the BPI-SF and
SF-MPQ-2 in various MSK conditions. Seven reports with ‘very good’ RoB ratings examined
the structural validity of the BPI-SF using factor analysis: four studies4,20,33,48 were classified
as ‘indeterminate’ because authors did not report details comparable to the COSMIN quality
criteria; the remaining three studies12,24,46 were ‘sufficient’ and displayed a high level of
evidence in support of the BPI-SF two-factor structure in MSK. Two articles suggested a two-
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factor solution explaining the BPI-SF severity and interference subscales was more optimal
than a three or one factor solution among mixed24 and low back pain46 patients, respectively.
Also, Farrere et al.12 confirmed the Portuguese interference subscale conformed with a onefactor solution, as originally hypothesized for the English version (Table 4).
Four studies examined the SF-MPQ-2 using factor analysis; however, pooled evidence
from two high quality studies (‘very good’ RoB rating) displayed a conflicting quality of
evidence in support of the SF-MPQ-2 factor structure in MSK condition. Although Dworkin
et al.11 proposed a four-factor solution for the SF-MPQ-2, all but the ‘neuropathic subscale’
did not confirm their proposed hypothesis. The study received a ‘very good’ risk of bias rating
but was ‘insufficient’ when compared against the COSMIN quality criteria. Conversely,
Lovejoy and co.25 showed that factor analysis indices (root mean square error of
approximation [RMSEA], Tucker-Lewis index [TLI], comparative fit index [CFI], Akaike
information criterion [AIC]) favoured a four-factor solution over a one-factor solution (Table
6); the study was ‘very good’ on RoB assessment and ‘sufficient’ against the COSMIN
quality criteria. Two studies were not included in the evidence synthesis: the first was
‘inadequate’ on RoB assessment because it was underpowered (less than 100 participants)29
while the other study1 was ‘indeterminate’ from the lack of comparable details with the
COSMIN criteria.
Turner and colleagues52 used a ‘very good’ methodology in their Rasch analysis of the
SF-MPQ-2 structure. Their findings suggest the SF-MPQ-2 is structurally unstable for use
among patients with knee pain: the total scale score exhibited some form of dimensionality
and differential item functioning. Furthermore, although the continuous, intermittent and
affective subscales were unidimensional, some item misfit (1, 8 and 9) and disordered
response thresholds were noted (Table 6). Packham et al.39 also examined the SF-MPQ-2
neuropathic subscale structural stability using Rasch analysis among complex regional pain
syndrome patients (CRPS). No signs of misfit or dimensionality was reported, and the level of
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item difficulty was adequate. Although the study received a ‘very good’ RoB rating, it was
underpowered (n= 57) and thus, of ‘insufficient’ quality according to COSMIN standards.
Overall, synthesis based on the COSMIN Modified GRADE suggest a ‘high’ level of
evidence of ‘sufficient’ quality supports the structural validity of the BPI-SF; hence, it
comparatively better than the SF-MPQ-2 with ‘high’ level of evidence but of ‘conflicting’
quality (Table 7).
Known-groups validity
Authors have tested a spectrum of hypotheses to confirm the ability of the two
outcome measures to differentiate known groups, but very few reports came from studies with
good methodological approaches. Of the ten hypotheses tested with the BPI-SF, only four
reports received ‘very good’ RoB ratings: Stubbs et al47 demonstrated the ability of the BPISF to discriminate elderly patients with mixed MSK conditions into known groups of
recurrent fallers and non-fallers, beyond chance (AUC, 0.72-0.73); however, two more
hypotheses posited in the same study about the BPI-SF ability to differentiate fallers from
none-fallers failed (AUC < 0.7).47 Six additional hypotheses20,46,55 examined the
discriminative ability of the BPI-SF to categorize back pain and osteoarthritis patients into
different groups of varying pain severities (Mild, Moderate, Severe, etc.). The findings were
rated ‘inadequate’ on RoB assessment and ‘indeterminate’ against the COSMIN quality
criteria from the use of poor statistical approaches and unclear definitions of known groups
(Table 4 ), which was not different from our findings among the studies that reported on the
SF-MPQ-2 known group validity11,25 (Table 6).
To conclude, the COSMIN Modified GRADE indicates a ‘moderate’ level of evidence
of ‘sufficient’ quality supports the BPI-SF known group validity in MSK studies while a ‘very
low’ level of evidence of an ‘indeterminant’ quality supports the SF-MPQ-2 known group
validity in MSK conditions (Table 7).
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Criterion-convergent validity
Criterion-convergent validity was the most investigated psychometric property on the
two questionnaires. A sizable number of health-related outcome measures (n=22) correlated
with the BPI-SF and SF-MPQ-2 in different MSK populations, and all but 2 studies received
‘very good’ and ‘sufficient’ ratings on RoB assessment and against the COSMIN quality
criteria. Furthermore, established correlations were mostly low-to-moderate in magnitude
(BPI-SF, 78%; SF-MPQ-2, 67%) (Table 4 & 6).
When disease/region specific PROMs like the Western Ontario and McMaster
Universities Arthritis Index, Oswestry Disability Index, Roland Morris Disability
Questionnaire were associated with subscales of the BPI-SF18,20,22,33,46,48,55 and SF-MPQ-2, 17
relationships were predominantly low-to-moderate (r = 0.3-0.69). Similarly, low-to-moderate
(r = 0.3-0.67) correlations were observed with mental/psychological status questionnaires: for
instance, the SF-MPQ-2 correlated with the Beck Depression Inventory (BDI-II), the
Generalized Anxiety Disorder-7 scale (GAD-7) and the Hospital Anxiety and Depression
Scale,11,25 while the BPI-SF subscales demonstrated an association with the Hospital Anxiety
and Depression Scale.12,20
When generic PROMs were associated with the two questionnaires, correlations were
mostly low-to-moderate (0.3-0.69) (Table 4 & 6); however, a few high associations (r ≥ 0.7)
were seen in Mixed-MSK studies between subscales of the BPI-SF and the Short Form Health
Questionnaire (SF 36)20 and the Chronic Pain Grade scale.20,22 Similarly, the SF-MPQ-2
correlated highly (r ≥ 0.7) with the pain Numeric Rating Scale and the Pain Disability Index
among complex regional pain syndrome patients;39 the Visual Analogy Scale1 and the
Multidimensional Pain Index25 in a mixed-MSK population, and with the SF-MPQ-2 parent
versions (MPQ and SF-MPQ) among patients with knee pain.29 In summary, a ‘high’ level of
evidence of ‘sufficient’ quality supports both tools criterion-convergent validities in MSK
populations, and established correlations were predominantly low-to-moderate in magnitude
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(r = 0.3-0.69) although a few higher correlations were seen with generic tools in mixed
studies.
Responsiveness
The responsiveness of the BPI-SF was more extensively investigated than the SFMPQ-2 in MSK conditions. Eighteen reports14,18–21,45,48,54 were available on the BPI-SF
responsiveness, but only five14,19,21,54 received ‘very good’ RoB and ‘sufficient’ quality
ratings. Two good quality studies, based on the construct approach, reported low-to-moderate
correlations (0.30-0.69) between change scores of the BPI-SF, and the generic EQ-5D54 (low
back pain) and disease-specific Osteoporosis Quality of Life Questionnaire14 (osteoporosis
patients). The receiver operator curve (ROC) approach was adopted in the remaining three
‘good’ quality studies: in one report, the BPI-SF subscale was able to discriminate improved
low back pain patients beyond chance (AUC ≥ 0.7)54; the other two reports in Mixed-MSK
populations supported the ability of the BPI-SF to discriminate patients that experienced ‘any
improvement’ from those with ‘moderate improvement’.19,21 However, the interference
subscale did not satisfy the review teams criteria (AUC > 0.7).19
Nine reports18–21,45,54 based on the effect size (ES) and standardized response mean
(SRM) approach to responsiveness, were rated ‘adequate’ on RoB assessment but
‘indeterminate’ against the quality criteria. All nine reports lacked clearly stated hypotheses
that defined the magnitude and direction of expected change: for instance, it was impossible to
tell if the reported ES or SRM supported the effectiveness of administered interventions, or
the responsiveness of the outcome measure to capture change as expected.36 Four reports from
three studies20,48,55 were also rated ‘inadequate’ and ‘insufficient’ from their poor design or
use of suboptimal statistical approaches, such as Guyatt statistic, co-variances, t-test statistic
or significant P-values (Table 5).
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Four studies1,11,25,39 addressed the SF-MPQ-2 responsiveness in MSK conditions: one39
among CRPS patients was ‘adequate’ on RoB assessment but ‘indeterminant’ against the
COSMIN quality standards because the authors did not define the expected change directions
or magnitude. The remaining three studies were ‘inadequate’ and ‘indeterminant’ because
authors employed suboptimal statistical approaches (Table 6). In summary, evidence
synthesis according to the COSMIN Modified GRADE suggest the BPI-SF has a ‘high’ level
of evidence of ‘sufficient’ quality in support of its responsiveness from 5 studies. On the
contrary, a ‘very low’ level of evidence of ‘indeterminant’ quality was seen across seven
studies for the responsiveness of the SF-MPQ-2.
DISCUSSION
Our systematic review indicates that better quality of evidence currently supports the
psychometric properties of the BPI-SF over the SF-MPQ-2. Although not a head-to-head
comparison, evidence synthesis based on COSMIN guidelines36–38,41,42,49 suggest both tools
have high-quality evidence supporting their internal consistency and criterion-convergent
validities. However, sufficient evidence of high-to-moderate quality only supports the BPI-SF
responsiveness, retest reliability, known group validity and structural validities as compared to
the SF-MPQ-2 in MSK conditions (Table 7). In addition, more articles described floor effects
on the SF-MPQ-2 than was reported with the use of the BPI-SF.
Two different, but complementary approaches to appraising the quality of
measurement evidence of outcome tools were employed in this review. Although quality
ratings favoured the SF-MPQ-2 over the BPI-SF when the structured clinical quality
assessment tool was used, quality assessed according to the COSMIN guidelines favoured the
BPI-SF. The SF-MPQ-2 only received higher quality rating in the initial phase of assessment
because it was often the primary focus of psychometric investigations, not because the reports
were void of bias. However, more studies were available on the BPI-SF and a reasonable
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number assessed measurement properties with sound methodological approaches which
favoured the BPI-SF quality ratings when assessed with the COSMIN guidelines. This finding
suggest that the quality or comprehensiveness of a study report does not rule out the
tendencies of bias in the evidence; however, insufficient reporting can expose otherwise good
evidence to bias.
Many of the included studies (42%) reported remarkable floor effects on select
subscales of the SF-MPQ-2. This may relate to the quality/characteristic of pain captured on
the 22-item descriptors of the SF-MPQ-2.10 Not all characteristics of pain may be similarly
represented in MSK conditions and the variation in patient scores on the SF-MPQ-2 subscales
may selectively reflect unique pain phenotypes within MSK conditions. This ultimately
predisposes some of the subscales of the SF-MPQ-2 to floor effect. For instance, high mean
scores on the neuropathic pain subscale is unlikely if participants perceive pain as nociceptive.
Similarly, it is unlikely for very resilient participants to report high scores on the SF-MPQ-2
affective subscale. Therefore, the floor effect on subscales of the SF-MPQ-2 does not
necessarily represent redundancy but reflect its discriminative nature. Future studies may
explore this speculation.
The available high-quality evidence on internal consistency and structural validity
supports the stability of the BPI-SF. Cronbach alpha was satisfactory and the original 2-factor
structure (severity and interference), as hypothesized during the BPI-SF development, was
reproduced.7,8 However, it was notable that several studies4,20,33,48 had an indeterminate
quality assessment rating because authors failed to report comparable indices even though
they mostly suppose the BPI-SF conforms with a 2-factor solution (Table 4). There is yet to
be a Rasch analysis on the BPI-SF structural validity in a well-represented MSK population;
the single Rasch paper identified during screening53 failed to satisfy our inclusion criteria ≥
70% threshold for MSK participants. Therefore, future authors should review the COSMIN
quality criteria36 when planning and documenting studies on the structural validity of the BPI48

SF, and a Rasch analysis should be performed in a population that sufficiently represents a
spectrum of musculoskeletal conditions.
For the SF-MPQ-2, internal consistency was established, but a conflicting (+/-) quality
of evidence displayed with its use in different MSK conditions. This happens periodically
with multidimensional tools and may suggest that the questionnaire’s factor structure varies
with the context of use.2 Mixed results of the item response examination of the SF-MPQ-2
using Rasch methods has been documented. Packham and colleagues36 utilized ‘very good’
methods to examine the SF-MPQ-2 neuropathic subscale with the Rasch. Although their
evidence supported the independent use of the neuropathic scale for CRPS assessment, the
study was rated insufficient according to the COSMIN quality criteria because of its small
sample size (n=57). In contrast, Turner and colleagues52 showed that the SF-MPQ-2 structure
did not fit with the Rasch as assessed among a representative sample of knee pain subjects.
Overall, it is too early to draw conclusions from the conflicting evidence on the SF-MPQ-2
structural validity in MSK conditions until more high-quality evidence emerges from studies
conducted in different MSK populations. Pooled evidence from such studies could be
synthesized to provide conclusive evidence in future reviews on the SF-MPQ-2.
Evidence for convergent-criterion related validities have been reported for both
assessment tools in studies of high quality. It was noteworthy that the reported correlation
with disease-specific/regional tools were consistently low-to-moderate (rho = 0.3-0.69) in
most of the included studies. This could be from differences in concepts used to describe pain
in generic and specific tools. While generic tools are structured to capture pain in multiple
conditions, specific/regional tools are designed to elicit responses on patients’ pain in
homogenous conditions. Although not entirely clear, these differences could underpin why
correlations were only low-to-moderate when the tools were used in homogenous conditions.
Test-retest reliability was among the least examined measurement properties across
the articles: estimates on measurement error (SEM and MDC) were completely lacking. Only
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the interference subscale of the BPI-SF has been shown to have satisfactory intraclass
correlation coefficient in support of its test-retest reliability and has received a high-quality
rating for use in MSK conditions. Both the BPI-SF severity subscale and the SF-MPQ-2
questionnaire lack high quality studies on their retest reliability. Some recurring flaws
identified during the risk of bias assessment included: a) non-specification of the ICC model
used in study analysis, preferably the two-way random effect model,36 b) low sample sizes, c)
employment of suboptimal retest-intervals, and d) the unverified assumption of participant
stability. Therefore, well-powered high-quality studies that measure the test-retest reliability
of the BPI-SF severity subscale and the SF-MPQ-2 are needed. Again, authors should
consider adhering to the COSMIN reporting guidelines, and vague descriptions of patient
stability should be avoided; if necessary, a Global Rating of Change score can be used to
confirm stability in doubtful situations. Finally, robust estimates on the measurement error
indices (SEM and MDC) of both tools should be pursued in different MSK populations.
One of the most important findings from this review relates to evidence backing the
two questionnaires responsiveness and known group validity in MSK conditions. Although
high quality evidence supports the BPI-SF responsiveness in MSK conditions,14,19,21,54 studies
that assessed responsiveness using the standardized response mean (SRM) and effect size
(ES) were ‘indeterminant’ because authors did not provide well-defined hypotheses with clear
magnitude and direction of expected change.36,38 The expected effectiveness or ineffectiveness
of interventions differ and hypotheses testing responsiveness have to be precise and based on
the context. For instance, smaller outcome measure change score indices are predicted in a
study of a specific low intensity intervention than a high intensity intervention in the same
population. Although the reported change scores would differ, both would generate support
for the ability of the measure to detect change if the change scores were proportional to the
intervention intensity. It is possible that authors ignored the importance of documenting this
evidence, or, such hypotheses were not defined initially in study protocols because most
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computations of ES and SRM responsiveness indices came from RCTs which had a secondary
aim of examining outcome measurement performance.19,21,54,55 For known group validity, we
only observed a moderate level of evidence in support of the BPI-SF since the available
evidence of sufficient quality focused on older adults (indirectness). Future studies examining
the responsiveness of BPI-SF, based on the ES and SRM approach need to provide precise
hypotheses that specify the magnitude and direction of expected change. Furthermore, high
quality studies are still needed in diverse age groups to explore known group validity of the
BPI-SF. Unfortunately, we are unsure of the evidence on the known group validity and
responsiveness of the SF-MPQ-2 in MSK population because studies of ‘very low’ and
indeterminant quality rating were found for both properties in MSK conditions. This gap
should be addressed in high-quality studies, bearing in mind that the SF-MPQ-2 was primarily
developed/expanded to be able to discriminate patients by the quality of pain they
experience,10 and it is highly important that clinicians/researchers are sure that a pain
assessment tool is able to detect a change in the patient’s condition.2,28,32
Valid and accurate MCID and CID estimates are important for outcomes evaluation,
prognostication and communication among health care professionals.28,32,44 Unfortunately,
only one well-powered study has reported the MCID and CID indices of the BPI-SF severity
subscale and the average pain item among fibromyalgia using the anchor-based approach.45
This lone report, however, is inadequate to permit informed decision-making considering the
diversity of MSK conditions with multiple conditions requiring estimates on their MCID and
CID, and the lack of estimate for the interference subscale. Even worst, no study has assessed
the SF-MPQ-2 MCID and CID in any MSK population. Multiple studies aimed at estimating
the MCID and CID of the two questionnaires are urgently recommended since these estimates
determine the level of significance associated with treatments when clinicians/researchers use
the tools.2,27,28
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In the present review, different ‘mixed’ and ‘specific’ MSK conditions were
investigated with the two questionnaires but it was obvious that none of the studies
exclusively reported the measurement properties of the tools in upper extremity conditions
(e.g. carpal tunnel syndrome, tennis elbow, shoulder pain/dysfunction) and neck-related MSK
conditions. Nonetheless, categories of MSK conditions such as neck and shoulder pain are
common and frequently present to clinicians. Future studies should consider investigating the
two questionnaires measurement properties in these classes of MSK conditions. Moreover, it
will be of great benefit to the clinician managing mixed or peculiar upper extremity and neck
MSK pathologies to be able to use outcome measures that not only assess the
multidimensional nature of pain, but at the same time yield scores comparable across different
studies.
LIMITATIONS
Our study has some limitations. First, our inclusion criteria considered only studies
reporting measurement properties from sample populations with ≥70% MSK sufferers.
Therefore, relevant reports of individuals with MSK disorders may have been overlooked or
omitted because the reports did not meet our defined inclusion criteria. Second, we were
unable to conduct a meta-analysis on the reported measurement properties across the included
studies. This was due to gross differences in study methodology, MSK population
characteristics, and the time intervals adopted in individual studies. However, our summary
tables and narrative synthesis should be comprehensive enough to allow the
clinician/researcher to understand the measurement properties accompanying the tools in
peculiar MSK conditions, while at the same time, having an idea of their general performance
in MSK conditions.
Third, in comparing the measurement properties of the two questionnaires, based on
the COSMIN Modified GRADE approach, we did not acknowledge the differences in their
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culturally adapted/translated versions. While clinometric experts discourage this, it may not be
problematic in this review because the evidence backing the culturally adapted/translated
versions were mostly similar to the original versions. For example, culturally
adapted/translated versions and original versions exhibited similar factor structures, their
internal consistency estimates were within a similar range, and when cross-cultural
adaptations were performed, authors confirmed compliance with standardized procedures to
ensure content reflected the same concepts with the tools’ original versions. Nonetheless,
specific details on the adapted/translated versions measurement properties and their quality
ratings are available for consideration in our result Tables 3 to 6.
CONCLUSION
Although the SF-MPQ-2 presents potential, a greater volume of better-quality
evidence was found in support of the BPI-SF measurement properties, including its
responsiveness, retest reliability, known group validity and structural validities, which suggest
it is currently better for pain assessment in MSK condition. Further investigation of (a) the
retest reliability of the BPI-SF severity subscale; (b) the SF-MPQ-2 structural validity, known
group validity, retest reliabilities, and responsiveness; and (c) the two questionnaires crosscultural validities, interpretability properties (MCID and CID), and measurement error indices
(SEM and MDC) is needed in multiple MSK studies of high quality.
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TABLE 1.

CHARACTERISTICS OF STUDIES ADDRESSING PSYHCOMETRICS OF THE BPI-SF AND SF-MPQ-2

First Author (Year)
Country;
Setting;
Version

Population

Design

Sample Characteristics

Measurement
Properties
Evaluated

Intervention/Retest

Celik (2017)4
Turkey;
3-outpatient
physiotherapy dept.;
BPI-SF (Turkish
version)

Patients: Turkish speaking
patients previously on routine
outpatient physiotherapy
MSK distribution: 13.8%
Upper extremity; 20.9%
Lower extremity; 65.3%
Spine

Cross sectional

N = 287
Sex = Males, 26.9%
Age = M, 49.72 (SD 12.92)
yrs.

Reliability
Validity

Intervention: Usual care
Retest: Baseline, general
baseline & 7days, n=71-testretest.

Group O. (1997)14
Canada;
Rheumatologist practice
(Canada) and 4
metabolic bone diseases
practice USA;
BPI-SF (English)

Patients: Patients who had at
least one osteoporosisinduced vertebral fracture
with a clinical diagnosis of
chronic back pain and (or)
osteoarthritis

Longitudinal
cohort

N = 226
Sex = Females, 100%
Age = 50yrs and above

Responsiveness

Intervention: Oestrogen
replacement therapy; Cyclic
Etidronate; Calcium;
Calcitonin
Retest: Baseline, 2weeks
and 6months

Ferreira-Valente
(2012)12
Portugal;
7 health institutions;
BPI-SF (Portuguese
version
*focused on
Interference scale

Patients: Participants
recruited had a history of
chronic MSK lasting 2years
(71%) and 10years (38.2%)

Crosssectional
Study

N = 214
Sex = Females, 66.1%
Age = M, 60.18 (SD 14.87)
yrs.

Validity
Reliability

Intervention: non
Retest: Baseline.

Kapstad (2010)18
Norway;
6 hospitals in 3
counties;
BPI-SF (Norwegian
version)

Patients: Patients on wait-list
for total hip replacement
surgery and had satisfactory
proficiency of the Norwegian
language

Prospective
cohort

N = 250
Sex = Females, 70%
Age = M, 68.7 (SD 9.9) yrs.

Validity
Reliability
Responsiveness
Floor or ceiling
effect

Intervention: Total hip
replacement surgery
Retest: Baseline and 1-year
post-surgery

Kean (2016)19
USA;
5 primary care centres
for Veteran in
Indianapolis;
BPI-SF (English)

Source: Pooled data from a
study on veterans with
moderate to severe persistent
musculoskeletal pain
MSK distribution:
Fibromyalgia, wide spread
pain, pain at the joints, limbs,
back and neck

RCT

N = 244
Sex = Females, 83%
Age = M, 55.1 yrs.

Responsiveness

Keller(2004)20
USA;
10 primary care centres;
BPI-SF (English)

Patients: Patients had a
primary diagnosis of
osteoarthritis, rheumatoid
arthritis, low back pain (on
workers’ compensation) and
Low Back Pain (not on
workers’ compensation)

Cross sectional

N = 250
Sex (not reported)
Age (not reported)

Validity
Reliability
Responsiveness

Intervention: Routine
treatment
Retest: Baseline and patients
next follow-up visit

Krebs (2009)22 and
(2010)21
USA;
10 primary health
centres;
BPI-SF (English)

Source: Pooled data from 3
studies. The authors
compared the responsiveness
of 4 outcome measures
MSK distribution: Majorly at
the lower back, hip and knee
region

RCT;
Longitudinal
Cohort

N = 427
Sex = 53.7%
Age = M, 59.1 (SD 13) yrs.

Responsiveness
Validity

Intervention: Depression
medication + Pain-self
management VS
Usual care
Retest: Baseline and 12
months

Lapane (2014)24
USA;
48 clinical sites;
BPI-SF (English)

Source: Pooled data from a
registry designed to provide
detailed prospective pain
assessment of oxycodone
users
MSK distribution: Above
70% of population with
mixed chronic MSK pain
including fibromyalgia,
arthritis, back and neck pain

Prospective
cohort

N = 741
Sex= Females, 59.6%
Age= M, 49.8 (SD 13.1) yrs.

Validity

Intervention: Prescribed
Oxycodone prescription
Retest: Baseline

Intervention: Not
described
Retest: Baseline and 3
months interval
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CONTINUED.
Mease (2011)31
USA;
not specified;
BPI-SF (English)
*focused on average
pain and severity pain
scores

Source: Pooled data from 4
RCTs. Participants all had a
diagnosis of fibromyalgia
and were randomized into
control and placebo groups

RCT

N = 1411
Sex = Females, 94.9%
Age = M, 50.3 (SD 10.44)
yrs.

Interpretability
(MCID and
CID)

Intervention: Control group
- duloxetine
Placebo group – sham
Retest: Baseline and 12
weeks

Mendoza (2006)33
USA;
(not specified);
BPI-SF; 10 items
Modified short form
(English)

Source: Pooled data from 2
RCT studies. Participants
suffering from Hip OA
(study 1) and knee OA (study
2) were recruited and
randomized into control and
placebo groups

RCT

N = 467 & 1019
Sex = Males ≈ 35.3%
Age ≈ M, 62.3 yrs.

Validity
Reliability

Intervention: Valdecoxib +
Naproxen
Retest: Baseline, 1 week,
and 2 weeks

Risser (2013)45
USA;
Not specified;
BPI-SF (English)
*focused on average
pain scale
Song (2016)46
Taiwan;
Physiotherapy
department;
BPI-SF (Chinese
version)

Source: Pooled data from 2
RCT studies. Participants had
knee pain in the last 3months
for a duration of at least 14
days/1-month

RCT

N = 524
Sex = Females, 57.1%
Age = M, 61 yrs.

Responsiveness

Intervention: Control
NSAID + Duloxetine
Placebo: Sham
Retest: Baseline and
24hours

Patients: Participants
recruited had a diagnosis of
Low back pain from
conditions including
spondylolysis,
spondylolisthesis, herniated
intervertebral disc, scoliosis
and sciatica

Crosssectional

N = 271
Sex = Males, 119; Females,
152
Age = M, 57.1 (SD 16.2) yrs.

Validity

Intervention: None
Retest: Baseline

Stubbs (2015)47
United Kingdom;
10 elderly homes;
BPI-SF (English)

Patient: Older adults were
surveyed in elderly homes on
falls resulting from chronic
MSK pain. They were
divided into 2 groups: study
group (with fall), and control
group (without fall or MSK)
to be compared

Cross sectional

N = 298
Sex = females ≈ 67.4%
Age = M, 76.6 (SD 8.5) yrs.

Validity

Intervention: None
Retest: Baseline

Tan (2003)48
USA;
Chronic pain unit of
Veteran affairs medical
centre;
BPI-SF (English)

Patient: Participants were
referred from several
specialities, including
surgery, rheumatology,
physical medicine and
rehabilitation
MSK distribution: About
50% reported pain of
multiple sites (including back
pain), and 28.8% reported
primary back pain

Cross sectional

N = 440
Sex = Males, 91.8%
Age = M, 54.9 yrs.

Validity
Reliability
Responsiveness

Intervention: Usual care
Retest: Baseline and followup visits

Whynes (2013)54
United Kingdom;
Nottingham - setting
(Not described);
BPI-SF (English)

Source: Pooled data was
from participants in a study
of epidural steroid injections
to alleviate low back pain

RCT

N = 37
Sex (not reported)
Age (not reported)

Responsiveness

Intervention: Epidural
injection
Retest: Baseline, 7days, and
12 weeks

Williams (2006)55
USA;
Multiple Medical
centre;
BPI-SF (English)
*Focus on interference
scale

Source: Pooled data from 2
studies conducted on
participants with a primary
diagnosis of OA at any
region and history of
moderate to severe pain for at
least 1 month

RCT

N = 106 & 239
Sex = Females, 62.5 &
72.9%
Age ≈ M, 63.1 (SD 9.8) yrs.

Validity
Reliability
Responsiveness

Intervention: Controlled
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release Oxycodone
Retest: Study 1Baseline, 7days, 14day;
Study 2- Baseline,
15,30,45,60, 90 days; Test
retest- Day 7 – Day 14

CONTINUED.
Adelmanesh (2012)1
IRAN;
Tertiary Pain & Rehab
clinic;
SF-MPQ-2 (Persian)

Patient: Mixed sub-acute and
chronic pain patients;
Persian-speaking; 74-patients
with diabetic neuropathic;
184-patient with pain
including myofascial pain,
epicondylitis, knee and neck
OA, Low back pain

Cross sectional

N = 258
Sex = Female, 55%
Age = M, 42.53 (SD 11.93)
yrs.

Validity
Reliability
Responsiveness

Intervention:
a.) Diabetic neuropathic
patients: pre-gabalin, shoe
modification education, and
physiotherapy)
b.) MSK patients: Physical
therapy, Acupuncture,
NSAIDS
Retest: Baseline and 3weeks; Test-retest, baseline
and 7-hours

Dworkin (2014)11 &
Turk (2015)51
USA;
Research setting of an
RCT study, not
specified;
SF-MPQ-2 (English)

Patients: Acute low back pain
patients with radiating pain to
at least one leg. Pain duration
was within 30days

RCT

N = 664
Sex= Males, 50%
Age= M, 45 yrs.

Validity
Reliability
Responsiveness
Floor or Ceiling
effect

Intervention: Oxycodone
and Tanpotalone
Retest: Baseline & 10days

Kachooei (2014)17
IRAN;
Knee pain clinic;
SF-MPQ-2 (Persian)

Patient: Knee OA patients
above 20years with a
diagnosis of Knee pain for at
least 6months. Knee OA
confirmed via X-ray

Cross sectional

N = 100
Sex = 80, Male; Female, 20
Age = M, 53 yrs.

Validity
Reliability

Intervention: None
Retest: Baseline & 3days

Lovejoy (2012)25
USA;
Recruitment site
including Hepatology
clinics, Veteran Affairs
Clinics, Primary care
setting, Mental Health
Classes;
SF-MPQ-2 (English)

Patient: Mixed chronic pain
population including MSK
conditions like neck/joint
pain (76%); low back pain
(59%); Rheumatism (53%);
and fibromyalgia

Cross sectional

N = 214
Sex = 93%, Male
Age = M, 54.4 yrs.

Validity
Reliability
Floor or ceiling
effect

Intervention: None
Retest: Baseline

Maruo (2014)29
JAPAN;
Two pain clinics,
University Hospital
Ortho & Neuro Surgery
Depts.;
SF-MPQ-2 (Japanese
version)

Patients: Mixed Japanese
speaking chronic pain
patients
MSK distribution: Knee and
hip OA, lumbar and cervical
radiculopathy

Cross sectional

N = 96
Sex = Female, 51%
Age: =M, 66 yrs.

Reliability
Validity

Intervention: None
Retest: Baseline & 3month

Packham (2018)39
NEW ZEALAND;
Different community &
hospital clinics;
SF-MPQ-2 (English)
*Focus on
Neuropathic subscale

Patients: English speaking
adults with type-1 CRPS, as
per, IASP classification,
affecting any limb; no prior
history of CRPS

Longitudinal
cohort

N = 59
Sex = Female, 72.9%
Age = M, 48.2 (SD 13.3) yrs.

Rasch analysis
Validity
Reliability
Responsiveness

Intervention: Not described
Retest: Baseline, 6 and 12
months

Turner (2017)52
UNITED KINGDOM;
University clinics,
Private settings in
Nottinghamshire
County;
SF-MPQ-2(English)

Patients: Patients had
primary diagnoses of Knee
OA. Patients were excluded
if they had surgery 3-months
before the study

Rasch analysis

N = 255; Follow Up = 113
Sex = Male, 42.4%
Age = M, 68 (SD 9.6) yrs.

Rasch analysis
Reliability
Responsiveness

Intervention: Knee
replacement surgery
Retest: Baseline and
6months
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TABLE 2: QUALITY OF STUDY REPORTS (ARRANGED HIGHEST TO LOWEST)
ITEM EVALUATION CRITERIA (SEE KEY BELOW)
REFERENCED STUDY

1

2

3

4

5

6

7

8

9

10

11

12

Total (%)

Lapane (2014)24

2

2

2

0

1

NA

2

2

2

2

2

2

86

Stubbs (2015)47

2

2

1

0

2

NA

1

2

2

2

2

2

82

1

2

1

2

2

NA

2

2

2

2

1

1

82

Keller (2004)20

2

2

2

2

1

NA

2

2

2

1

1

2

79

31

2

2

1

0

1

NA

1

2

2

2

2

2

77.

2

1

2

2

1

NA

1

1

2

2

1

1

73

2

1

1

2

1

1

1

1

2

1

2

2

70

Song (2016)46

2

2

1

0

1

NA

2

1

2

1

2

1

68

Celik (2017)4

1

2

1

2

1

2

1

1

2

2

0

1

67

2

1

1

1

1

NA

1

1

2

1

1

1

59

0

2

1

0

2

NA

1

2

2

2

1

0

59

1

1

1

0

0

NA

2

2

2

2

2

0

59

2

1

1

2

1

1

0

1

2

1

1

1

58

0

1

1

1

1

NA

1

1

2

2

1

1

55

0

2

1

0

1

NA

1

1

2

2

2

0

55

0

1

1

0

1

NA

0

1

2

2

2

0

50

2

2

1

2

1

NA

2

2

2

2

2

2

92

2

2

1

2

1

NA

2

2

2

2

2

2

91

2

2

1

2

0

NA

2

2

2

1

2

2

82

1

2

1

2

1

2

1

1

2

2

2

2

79

BPI-SF

Kapstad (2010)

Mease (2011)

18

Ferreira-Valente (2012)12
Williams (2006)

Tan (2003)

55

48

Group O. (1997)14
Whynes (2013)

54

Mendoza (2006)33
Krebs (2009 and 2010)

21,22

Kean (2016)19
Risser (2013)

45

SF-MPQ-2
Dworkin (2014)11 & Turk (2015)51
Lovejoy (2012)

25

Packham (2018)39
Maruo (2014)

29

66

Turner (2017)52
Kachooei (2014)17
Adelmanesh (2012)

1

Percentage of studies that
received 2 points per criterion

2

2

1

2

2

0

1

1

2

1

2

1

71

1

2

1

2

0

NA

2

1

2

2

2

0

68

1

2

1

2

1

0

2

1

2

1

1

1

65

54

67

12

54

16

33

41

41

100

62

58

34

KEY:
1.

Thorough literature review to define research question

8.

Measurement techniques were standardization and significantly void of

2.

Description of setting and participants (inclusion/exclusion criteria)

3.

Specific Hypothesis

9.

4.

Appropriate scope of psychometric properties

10. Selection of appropriate statistical test

5.

Sample size

11. Use of benchmarks and confidence interval

6.

Follow-up/retention

12. Valid conclusion and clinical recommendation

7.

The authors referenced specific procedures for administration, scoring,
and interpretation of procedures

bias
Data were presented for each hypothesis

Total score = (sum of subtotals ÷ 24 × 100). If for a specific paper an item is deemed NA (Not Applicable), then, Total score = (sum of subtotals ÷ (2 × number of Applicable items) ×
100)
Quality Summary: Poor (0%–30%), Fair (31%–50%), Good (51%–70%), Very good (71%–90%), Excellent (> 90%)
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TABLE 3: SUMMARY OF BPI-SF TEST RETEST RELIABILITY, INTERNAL CONSISTENCY AND QUALITY RATING
Psychometric
properties
Internal
consistency;

Authors and Extracted Data
95% confidence interval Cronbach alpha (α) coefficients:
•
Turkish version; Pain severity = 0.84; Pain interference = 0.89
(Celik et al.)4
•
Pain severity = 0.85; Pain interference = 0.88
(Tan et al.)48
•
Pain severity and pain interference (Mood and activity) scales = 0.86 - 0.96
(Mendoza et al.)33
•
Portuguese version; Pain interference = 0.91
(Ferreira-Valente et al.)12
•
Pain interference = 0.82 - 0.89
(William et al.)55
•
Norwegian version; Pain severity = 0.87; Pain interference = 0.88
(Kapstad et al.)18
•
Arthritis patients; pain interference = 0.95; pain severity = 0.89
(Keller et al.)20

Population

Risk of
Bias

Quality
rating

Mixed-MSK

Very good

+

Mixed-MSK

Very good

+

Mixed-MSK

Adequate

+

Mixed-MSK

Very good

+

Specific-arthritis

Very good

+

Specific-Hip pain

Very good

+

Specific- arthritis

Very good

+

Very good

+

adequate

+

Specific-arthritis

doubtful

?

Specific-Arthritis

Adequate

+

•

Test- retest

Specific-back pain
Lower back pain; pain interference = 0.93; pain severity = 0.82
(Keller et al.)20
Pooled evidence (range): BPI-SF severity and interference: 0.82-0.96, from 8 studies of very good to adequate quality
GRADE of evidence: High
Mixed-MSK
• Sample size (n)= 71; Stable on no treatment; retest interval=7days; ICC = 0.84, Interference;
0.88, severity
(Celik et al.)4
•

•

Sample size (not specified); Patient status = assumed stable on medication; retest interval=
daily, for 7 days:
a. Pain severity, Pearson correlation(r)= 0.67-0.88.
b. Mood-related Interference Pearson correlation (r) = 0.68-0.93.
c. Activity related interference, Pearson correlation (r) = 0.70-0.91 (Mendoza et al.)33
Sample size (n)=43; Assumed stable on high pain medication; 1 week interval (7days-14days):
ICC = 0.81, interference (William et al.)55
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a.) Pooled evidence: Severity subscale, n=71, ICC = 0.84, from one study of adequate quality
GRADE of evidence = Low.
b.) Pooled evidence (Weighted average): Interference subscale n=114, ICC = 0.83, from two studies of adequate quality
GRADE of evidence = High
Quality rating Key: + = Sufficient; - = Insufficient; ? = Indeterminate; NA = not applicable
Levels of risk of bias ratings: Very good; Adequate; Doubtful; Inadequate
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TABLE 4: SUMMARY OF BPI-SF MCID & CID, FLOOR-CEILING EFFECT, VALIDITIES AND QUALITY RATINGS
Psychometric properties
Ceiling and floor effect
Clinically Important
Difference (CID)
Minimal Clinically
Important Difference
(MCID)

Authors and Extracted Data

Population

Risk of
bias

Quality
Rating

Floor effect – 1-year (After Total hip replacement): 24%, interference scale; 21%, Severity scale
(Kapstad et al.)18

Specific-Hip OA

NA

NA

•
•

Against Anchor – PGI-I 1/7 (among fibromyalgia patients)
BPI Severity scale: 2.79 (36.9% improvement)
BPI Average pain scale: 2.82 (43.4% improvement) (Mease et al.)31

Specific-Fibromyalgia

NA

NA

•
•

Against Anchor – PGI-I 1/7 (among fibromyalgia patients)
Severity = 2.16 points, (34.2% improvement)
Average pain score = 2.09 points (32.3% improvement) (Mease et al.)31

NA

NA

Specific-Arthritis

inadequate

?

Specific-Arthritis

inadequate

?

•

Specific-Fibromyalgia

(i.) Known group validities
Detected difference between:
(a) Interference scale only:
•
Study 1 Pain-level (arthritis): Low to moderate pain, M, 4.68 (SD, 2.0); High pain, M, 6.6 (SD,
1.9) (t130 = -5.66, P <0.0001)
(William et al.)55
•
Study 2 Pain-level (Low back pain): Low to moderate pain, M, 5.36 (SD, 1.7); High pain, M, 6.33
(SD, 1.7) (t104 = -2.73, P < 0.01) (William et al.)55
•

Differentiate level of disability in Low back pain: stratified by ODI; discriminates between
Mild, M, 1.61 (SD, 1.27) and Moderate, M, 3.20 (SD, 1.78);
Mild, M, 1.61 (SD, 1.27) and Severe, M, 4.37 (SD, 1.69);
Moderate, M, 3.20 (SD, 1.78) and Severe, M, 4.37 (SD, 1.69) (p value 0.01 - 0.001 ) (Song et
al.)46

Specific-Back pain

inadequate

?

•

Disability (CMP older adults): AUC = 0.663; >4.5 (Fallers from non-faller); AUC, 0.684; Mean,
4.7 (Recurrent fallers from single/non-fallers) (Stubbs et al.)47

Mixed-MSK

Very good

-

•

Disability (CMP older adults): AUC, 0.724 (95% CI 0.630–0.818); Mean, 4.6 (Recurrent fallers
from non-fallers) (Stubbs et al.)47

Mixed-MSK

Very good

+

Mixed-MSK

Very good

-

Mixed-MSK

Very good

+

Specific-Back pain

inadequate

?

(b) Severity subscale only:
•
Disability (CMP older adults): AUC, 0.665; Mean, >5.1(fallers from non-fallers); AUC, 0.679,
Mean, >5.3 (recurrent fallers from single/non-fallers) (Stubbs et al.)47
•
Disability (CMP older adults): AUC, 0.731 (95% CI 0.635–0.826); Mean, >5.1 (recurrent fallers
from non-fallers) (Stubbs et al.)47
•

Differentiate level of disability in Low back pain: stratified by ODI; discriminates between
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Mild M,2.47 (SD 1.52) and moderate, M, 3.48 (SD, 1.63); mild, M, 2.47 (SD, 1.52) and severe,
M, 3.94 (SD, 1.66); (p value 0.01 - 0.001)
(note: failed to differentiate moderate and severe p-value = 0.089) (Song et al.)46
(c) Interference and severity scale:
•
BPI-SF differentiates arthritis patients into varying pain severity as stratified on the
Anchor CPG:
Total scale MANOVA: F (6,182) = 17.58, P < 0.0001
Severity ANOVA: F (3,92) = 19.01, P < 0.0001
Interference ANOVA: F(3,92) = 39.39, P < 0.0001 (Keller et al.)20
•

BPI-SF differentiates Low back pain patients into varying pain severity as stratified on the
Anchor CPG:
Total scale MANOVA: F (6,204) = 14.66, P < 0.0001;
BPI Severity ANOVA: F (3,103) = 12.47, P < 0.0001;
BPI Interference ANOVA: F(3,103) = 33.82, P < 0.0001(Keller et al.)20

Specific-arthritis

inadequate

?

Specific-low back pain

inadequate

?

Mixed-MSK

Doubtful

-

Pooled evidence: 2 hypotheses confirmed in sufficient studies with “very good” quality rating.
GRADE of evidence: Moderate
(ii) Convergent/ Criterion
Validity

Change in Predicted Direction:
Change in BPI scores baseline to 7days, in concordance, with Patient global assessment of
arthritis rating of change from baseline to 14 days) (Mendoza et al.)33
Severity subscale: -2.35, Improved; -1.08, No change (CI 3.26 P < 0.001)
Activity-interference subscale: 0.76, Improved; -2.32, No change (CI 2.56 P < 0.001)
Mood-interference subscale: -1.19, improved; -2.21, No change (CI 3.95 P < 0.011)
Correlation with other scales reported as moderate (0.30-0.69):
Severity subscale only:
•

VAST& SF-BPI-Worst pain (Celik et al.)4

Mixed-MSK

Adequate

-

•

SF-36 (Physical function, mental, Role [emotional & physical], social function, vitality, general
health), CPG-disability, HAD-disability, RMDQ-disability (Keller et al.)20

Mixed-MSK

Very good

+

Mixed-MSK

Very good

+

Mixed-MSK

Very good

+

Specific-Arthritis

Very good

+

•
RMDQ-disability; CPG disability (Kreb et al. 2009)22
Interference subscale only:
•
SF-12 Mental health and physical function, NRSP, HADP-Activity & Disability
(Ferreira-Valente et al.)12
•

WOMAC, (pain, stiffness, physical function, pain at night in bed), ALQ, sleep quality, number of
night awakening (William et al.)55
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n

•

WOMAC (stiffness); SF-36 (role physical, role emotional, and general health) (Kapstad et al.)18

Specific-Hip OA

Very good

+

•

CPG intensity (Krebs et al. 2009)22

Mixed-MSK

Very good

+

Specific-Back pain

Very good

+

Both Interference and severity scale:
•
ODIc (Song et al.)46
•

VAS (pain), WOMAC (pain, physical function and stiffness) (Mendoza et al.)34

Specific-Arthritis

Very good

+

•

FMI, SF-36 body pain (Krebs et al. 2009)22

Mixed-MSK

Very good

+

•

WOMACn [Pain, Physical function); SF-36 (physical function, bodily pain, vitality, social
function and mental function) (Kapstad et al.)18
RMDQ-disability (Tan et al.)48

Specific-Hip OA

Very good

+

Mixed-MSK

Very good

+

Mixed-MSK

Very good

+

Mixed-MSK

Very good

+

Severity subscale only:
•
CPG intensity (Krebs et al. 2009)22

Mixed-MSK

Very good

+

Interference and severity subscale:
•
SF-36-body pain; CPG-Intensity(Keller et al.)20

Mixed-MSK

Very good

+

Mixed-MSK

Very good

+

•

Correlation with other scales reported as High (≥0.70):
Interference subscale only:
•
SF-36 (Vitality, mental health, physical & social function), CGP-disability; RMDQ-disability
(Keller et al.)20
•

•

CPG disability, RMQD-disability (Krebs et al. 2009)22

PEG, Overall pain stress (Krebs et al. 2009)22

Pool evidence: 15 PROs examined: 94% hypothesis confirmed; 24 (64%) hypothesis @ rho, 0.3-0.69;10 hypothesis @ rho
≥0.7
Grade of evidence: high
Structural validity; Factor
Analysis

Support 1 factor:
•
Confirmatory Factor Analysis; supports 1 factor structure (assessed only the Portuguese BPI-SF
interference); χ2 (14) =72.54, (p < 0.001), CFI = 0.91; SRMR = 0.06; CFI = 0.91; SRMR 0.06
(Ferreira-Valente et al.)12
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Mixed-MSK

Very good

+

Support 2 factor:
•
Confirmatory factor analysis with principle promax rotation; 56% variance accounted; 2 factor
structure (interference items & pain intensity) (Celik et al.)4

Mixed-MSK

Very good

?

•

Exploratory Factor analysis; principle promax rotation; 2 factor structure with 67% variance
accounted; eigenvalues > 1 (6.9 and 1.2);interitem correlation 0.59-0.88 (Keller et al.)20

Mixed-MSK

Very good

?

•

Compared a one, two & three factor model; 2 factor model (pain and interference) yielded best fit
with CFI 0.99, CI 0.04-0.07. RMSEA for 2 factor model was 0.05 compares to 1 factor model
(0.17) and 3 factor model (0.12) (Lapane et al.)24

Mixed-MSK

Very good

+

•

Supports 2 factor structure; confirmatory factor analysis; yielded 2 factor models (pain and
interference) with RMSEA 0.09, GFI 0.91, CFI 0.92; however, NFI - 0.89 and AGFI - 0.87 (>
0.90 required) and SRMR 0.39 (Song et al.)46

Specific-Back pain
Very good

+

Confirmatory factor analysis; promax rotation; support two factor (interference and pain)
accounting for 63.6% variance; eigenvalue 5.62 & 1.38 for interference and pain intensity
respectively (Tan et al.)48

Mixed-MSK

Very good

?

Specific-Arthritis

Very good

?

•

Support 3 factor:
•
Modified version of SF-BPI; confirmatory factor analysis; Oblique rotation; 3 factor structures
(pain, mood-interference and activity-interference); 86% variance accounted; eigenvalue range
0.9 - 5.1; in both studies, items “sleep” and “enjoyment of life” did not load properly and were
dropped (Mendoza et al.)33

Pooled evidence: “severity” and “interference” factor structures explained in 3 sufficient studies with “very good” quality
GRADE of evidence: High
Key: ODI, Oswestry Disability Index; PEG; 3-item SF-BPI (“pain average,” “interference with enjoyment of life,” and “interference with general activity”); CPG; Chronic Pain Grade; SF-36,Short Form-36
Health Status Questionnaire; SF-12, Short Form-12 Health Status Questionnaire; RMDQ, Roland Morris Disability Questionnaire; FMI, Functional Morbidity Index; WOMAC, Western Ontario and McMaster
Universities Osteoarthritis Index; HAD; Hospital Anxiety and Depression Scale; ALQ, Activities and Lifestyle Questionnaire; VAS, Visual Analogy Scale; NRS, Numerical Rating scale, CMP, Chronic
Musculoskeletal Pain; t, Turkish; c, Chinese; pg, Portuguese version; n, Norwegian; AGFI, adjusted goodness-of-fit index; χ2, chi-squared; CFI, comparative fit index; df, degree of freedom; GFI, goodness-of-fit
index; NFI, normed fit index; RMSEA, root mean squared error of approximation; SRMR, standardized root mean square residual; CI, Confidence interval; AUC, Area Under the ROC Curve; PGI-I, Patient

global impression of improvement
Quality rating Key: + = sufficient; - = insufficient; ? = indeterminate; NA = not applicable
Levels of Risk of Bias: Very good; Adequate; Doubtful; Inadequate

73

TABLE 5: SUMMARY OF BPI-SF RESPONSIVENESS AND QUALITY RATINGS
Psychometric properties

Authors and Extracted Data

Correlation of change scores

Cross sectional change correlation (Group O.)14
OQLD, physical= 0.72 and Symptom= 0.81 (baseline to 2 weeks)
Longitudinal change correlation
BPI-SF Severity: OQLD, physical= 0.38; Symptom= 0.48 (2 weeks to 12 months)
Cross sectional change correlation(Whynes et al.)54
BPI Severity: 0.52, 0DI; -0.59, EQ-5D-Index; -0.48, ED-5D-VAS
BPI interference: 0.61, 0DI; -0.63, EQ-5D-Index; -0.40, ED-5D-VAS
Similar pattern across other scales
Weekly change correlation
BPI Severity: -0.57, EQ-5D-Index; -0.56, ED-5D-VAS; 0.70, ODI
BPI Interference: -0.58, EQ-5D-Index; -0.50, ED-5D-VAS; 0.65, ODI
Similar pattern across other scales
Sensitivity to change in patient status (Krebs et al. 2010)21
AUC (Any improvement): Severity = 0.81-0.83; Interference = 0.70 - 0.78
AUC (Moderate Improvement): Severity = 0.81-0.85; Interference = 0.67-0.77
Better or similar to PEG, CPG, RMDQ, and SF-36-body pain
AUC (interference) = 0.80 (Whynes et al.)54
Sensitivity to change in patient status (Kean et al.)19
•
AUC (Severity): 0.727, any improvement; 0.737, moderate improvement
•
AUC(total): 0.727, any improvement; 0.743, moderate improvement
Better than PEG, SF-36 bodily pain, and PROMIS PI-6b SF; PROMIS P-SF (27 and 57)
•

AUC (interference): 0.677, any improvement; 0.694, Moderate improvement. (Kean et al.)19

Using MANOVA statistic, BPI significantly identified change in patients’ conditions (with 2-SEM
signalling change on BPI) among:
(a.) Arthritis (against HAD): [Wilks’ Lambda F(4,194) = 4.84, P < 0.001]
(b.) Low back pain (against RMDQ): [Wilks’ Lambda F (4,198) = 10.77, P < 0.0001]
(Keller et al.)20
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Population

Risk of bias

Quality
rating

Specific- Osteoporosis

Very good

+

Specific-Back pain

Very good

+

Mixed-MSK

Very good

+

Specific-Back pain

Very good

+

Mixed-MSK

Very good

+

Mixed MSK

Very good

-

Specific- Arthritis
Specific-Back pain

Inadequate
Inadequate

-

BPI responsiveness to detect interventional change across visits; Interval (27.73 days)
(Tan et al.)48
Mixed-MSK

Inadequate

-

Mixed-MSK

Adequate

?

Adequate

?

Specific-Back pain

Adequate

?

ES: Total RCT study = 0.64;
Back pain population = 0.60;
Hip/knee OA = 0.69 (Keller et al.)20

Mixed-MSK
Specific-Back pain
Specific- Arthritis

Adequate
Adequate
Adequate

?
?
?

ES: 0.53, BPI average pain item; Anchor, PRPI (0/10 scale); BPI average pain item similar to ICOAP
and (Anchor) PRPI but higher than WOMAC pain and ICOAP (Risser et al.)45

Specific-Knee pain

Adequate

?

Specific- Arthritis

Adequate

?

BPI
interference
BPI Severity

ES and SRM

Mean Change
1st visit
2nd visit
7.42
6.71

3rd visit
6.46

T-test/CI
2.52-5.33
P > 0.01-0.001

7.07

6.14

1.12-4.66
P > 0.01-0.001

6.63

Improvement rating similar with RMDQ and PEG; higher than generic outcomes like CPG and SF 36body pain.
SRM: better, -1.02; Worst, 0.37; Same, -0.18 (Krebs et al. 2010)21
Sensitivity to change; anchor (patient reported global change- item 1/7) 3-months; compared to SF-36
body pain, PEG and PROMIS PI-6b SF; PROMIS P-SF (27 and 57) (Kean et al.)19
•
SRM (Severity): Better, 0.71; Worst, -0.47; Same, 0.13
•
SRM (Interference): Better, 0.94; Worst, 0.03; Same, 0.38
•
SRM (Total): Better, 0.94; Worst, -0.22; Same, 0.31
SRM (interference and severity) = 0.90; higher than ODI (0.82) and EQ-5D (0.63-0.83) (Whynes et al.)54

12 months Responsiveness to intervention improvement in 2 different conditions
(Keller et al.)20
SRM
Categories
Improved
Same
Declined
Arthritis
BPI Intensity
-0.87
-0.55
0.01
BPI Interference
-0.84
-0.33
0.16
Low back pain
BPI Intensity
-1.09
-0.40
0.28
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Mixed-MSK

BPI Interference

•

0.43

BPI interference
1.71
1.52
2.05

Specific- back pain

Adequate

?

Specific-Hip pain

Adequate

?

Specific-Hip pain

Adequate

?

Specific-Arthritis

inadequate

-

BPI pain intensity
1.57
1.61
2.03

Magnitude of change on BPI scales; Anchor SF-36 perceived global change (1-7 scale); similarly
responsive as WOMAC (physical and stiffness), and more sensitive than other SF-36 subscales in THR
patient) (Kapstad et al.)18
Scale

•

-0.56

Magnitude of overall condition change (ES, SRM and RI), 12 months post THR (Kapstad et al.)18
Indicators
ES
SRM
RI

•

-1.13

BPI Intensity

Improved group
ES
SR
RI
M
1.70 1.71 2.17

Unchanged group
ES
SR
RI
M
1.00 1.36 1.39

BPI interference

1.80

1.27

1.81

2.16

1.40

1.56

Using Guyatt statistic, magnitude of change (BPI-Interference scale) between Control and Placebo
(Williams et al.)55
Intervals
0-7days
0-14days
0-30days
0-90days

Study 1: ES
0.46
1.06
-

Study 2: ES
0.84
0.95

Pooled evidence: 5 reports with “very good” quality rating available on responsiveness of the BPI-SF
GRADE of evidence: High
Key: AUC, Area Under the ROC Curve; CGP, Chronic Pain Grade; WOMAC, Western Ontario and McMasters Universities osteoarthritis index; ICOAP, Intermittent and Constant Osteoarthritis Pain; PRPI,
patient rated pain index; ; PEG, 3-item SF-BPI (“pain average,” “interference with enjoyment of life,” and “interference with general activity”); RMDQ, Roland Morris Disability Questionnaire; EQ-5D,
European Quality of Life Instrument (Version 5D); PROMIS PI-6b-SF, short-form Patient-Reported Outcomes Measurement Information System-6b (Interference scale); ODI, Oswestry Disability Index;
PROMIS P-SF (27 and 57), short-form-Patient-Reported Outcomes Measurement Information System Profile (29 and 57 item versions);SF-36,Short Form-36 Health Status Questionnaire; OQLD, Osteoporosis
Quality of Life Questionnaire; ES, Effect size; SRM, Standardized Response Mean; RI, Responsiveness Index
Quality rating Key: + = sufficient; - = insufficient; ? = indeterminate; NA = not applicable

Levels of Risk of Bias: Very good; Adequate; Doubtful; Inadequate
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TABLE 6. SUMMARY OF SF-MPQ-2 MEASUREMENT PROPERTIES AND THEIR QUALITY RATINGS IN MSK
Psychometric Properties
Floor and ceiling effect:

Hypothesis testing:
(i). Criterion/Convergent
Validity

Extracted Data and First Author
•

Floor effect: Affective Scale, 15.1%; Neuropathic Scale, 12.5% (Dworkin et al.)11

•

Floor effect: Affective, 28.5%; Neuropathic , 12.4%; Intermittent, 15.1% (Lovejoy et al.)25

•

Floor effect: Continuous, 4.6%; Intermittent, 4.2%; Neuropathic, 1.9%; Affective, 8.7; Total, 3.1%
(Adelmanesh et al.)1

Correlation with other measures reported as moderate (Pearson or Spearman rho=0.3-0.69):
Continuous scale:
• WOMACP; SF 36p (PH,BP,GH,RE,MH,MCS &PCS) (Kachooei et al.)17

MSKCategory

Risk of bias

Quality
Rating

Specific-Back
pain
Mixed-MSK

NA

NA

NA

NA

Mixed-MSK

NA

NA

Specific-Knee
pain
Specific-Back
pain

Very good

+

Very good

+

•

BPI severity (worst, least, average and current); NRS-average back pain, NRS-average leg pain;
NRS-current back pain; NRS-current leg pain; HAD-total; HAD-anxiety
(Dworkin, 2014 and Turk, 2015)11,51

•

MPI-interference; PDI; GAD-7; BDI-II (Lovejoy et al.)25

Mixed-MSK

Very good

+

•

VASJ; SF-MPQJ (sensory, affective, total); LF-MPQJ (sensory, affective, evaluative, total)
(Maruo et al.)29

Mixed-MSK

Very good

+

Very good

+

Very good

+

Intermittent scale:
• WOMACP; SF 36p (PF, BP, VT, GH, RE,MCS) (Kachooei et al.)17
•

BPI severity (worst, least, average and current); NRS-average back pain, NRS-average leg pain;
NRS-current back pain; NRS-current leg pain (Dworkin, 2014 and Turk, 2015)11,51

Specific-Knee
pain
Specific-Back
pain

•

MPI-interference; MPI-Severity; PDI; GAD-7; BDI-II (Lovejoy et al.)25

Mixed-MSK

Very good

+

•

VASJ; SF-MPQJ (sensory, affective, total); LF-MPQJ (sensory, affective, evaluative, total)
(Maruo et al.)29

Mixed-MSK

Very good

+

Very good

+

Very good

+

Very good

+

Neuropathic scale:
• WOMACP; SF 36p (PF, BP, PCS) (Kachooei et al.)17
•

BPI severity (least, average and current); NRS-average leg pain; NRS-current leg pain; HADtotal; HAD-anxiety (Dworkin, 2014 and Turk, 2015)11,51

Specific-Knee
pain
Specific-Back
pain

•

MPI-interference; MPI-Severity; PDI; GAD-7; BDI-II (Lovejoy et al.)25

Mixed-MSK
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•
•

VASJ; SF-MPQJ (sensory, affective, total); LF-MPQJ (sensory, affective, evaluative, total)
(Maruo et al.)29
CSS (Packham et al.)39

Affective scale:
• WOMACP; SF 36p (PF, RE, BP, VT, MH,MCS) (Kachooei et al.)17

Mixed-MSK

Very good

+

Specific-CRPS

Very good

+

Very good

+

Very good

+

•

BPI severity (least and average); NRS-average leg pain; NRS-current leg pain, HAD-Total,
HAD-Anxiety (Dworkin, 2014 and Turk, 2015)11,51

Specific-Knee
pain
Specific-Back
pain

•

MPI-interference; MPI-Severity; PDI; GAD-7; BDI-II (Lovejoy et al.)25

Mixed-MSK

Very good

+

•

SF-MPQJ (sensory, total); LF-MPQJ (sensory, affective, evaluative, total) (Maruo et al.)29

Mixed-MSK

Very good

+

Specific-Knee
pain
Specific-Back
pain

Very good

+

Very good

+

Total scale:
• WOMACP; SF 36p (PF,BP, GH, VT, RE,MH, PCS, MCS) (Kachooei et al.)17
•

BPI severity (worst, least, average and current); NRS-average back pain, NRS-average leg pain;
NRS-current back pain; NRS-current leg pain; HAD-total; HAD-anxiety
(Dworkin, 2014 and Turk, 2015)11,51

•

MPI-interference; PDI; GAD-7; BDI-II (Lovejoy et al.)25

Mixed-MSK

Very good

+

•

VASJ; SF-MPQJ (sensory, affective, total); LF-MPQJ (affective, evaluative) (Maruo et al.)29

Mixed-MSK

Very good

+

•

CSS (Packham et al.)39

Specific-CRPS

Very good

+

Mixed-MSK

Very good

+

Mixed-MSK

Very good

+

Neuropathic scale:
• NRS-pain, PDI (Packham et al)39

Specific-CRPS

Very good

+

Total scale:
• MPI-severity (Lovejoy et al.)25

Mixed-MSK

Very good

+

Correlation with other tools reported as High (Pearson or Spearman rho= ≥ 0.7):
Continuous scale:
• MPI-severity (Lovejoy et al.)25
Affective scale:
• SF-MPQJ-affective (Maruo et al.)29

•

NRS-pain, PDI (Packham et al)39

Specific-CRPS

Very good

+

•

VASP(Adelmanesh et al.)1

Mixed-MSK

Very good

+

•

LF-MPQJ-total, LF-MPQJ- sensory) (Maruo et al.)29

Mixed-MSK

Very good

+
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Pooled evidence: 14 PRO Comparators; 75 Hypothesis, rho = 0.3-0.69; 6 Hypothesis, rho = ≥ 0.7
GRADE of evidence: High
(ii.) Known group validity

SF-MPQ-2 Total OR subscales:
• Discriminant patient stratified by QTFC scale: 3, 4, & 6
Only total scale score extracted
QTFC category 3: total scale- M, 3.97 (SD, 2.03)
QTFC category 4 or 6: total scale- M, 4.49 (SD, 2.04) p-value = 0.001 (Dworkin et al.)11
• Differentiate patients by number of reported pain sites, were those with higher SF-MPQ-2 pain
scores indicated more pain sites.
Only total scale score extracted:
One pain site: M, 2.44 (SD 2.14);
Two-three pain site: M, 2.97 (SD 2.13)
Four or more pain site: M, 3.81 (SD 2.36) p-value = 0.05 (Lovejoy et al.)25
•

•

Discriminate patients stratified on MPI scale into:
Only total scale score extracted:
None/mild: M, 1.16 (SD, 1.61)
Moderate: M, 3.08 (SD 1.68)
Severe: M, 5.55 (SD 2.00) p-value = 0.05 (Lovejoy et al.)25
Differentiate patients stratified on PPI scale into:
Mild pain: M, 33.81, (SD 14.16) p-value = 0.041
Discomforting: 45.60 (SD 16.00) p-value = 0.028
Distressing: M 53.62 (SD 18.78) p-value = 0.032
Horrible: M, 58.49 (SD 18.97) p-value = 0.027 (Adelmanesh et al.)1

Specific-back
pain

inadequate

?

Mixed-MSK

inadequate

?

Mixed-MSK

inadequate

?

Mixed-MSK

inadequate

?

Pooled evidence: 4 hypotheses tested in studies with “inadequate” and “insufficient” quality rating.
GRADE of evidence: Very low
Structural validity;
Rasch analysis

SF-MPQ-2 Total OR subscales:
•
SF-MPQ-2 Continuous scale: Item 8 and 9 misfit; item 10 displays uniform DIF for gender; passed
unidimensionality test; removal of item 9 returns stability across structures; differential item
functioning present among gender group
•
SF-MPQ-2 Intermittent scale: Passed unidimensionality test; items 2 and 3 misfit; No DIF for
gender
•
SF MPQ-2 Neuropathic Scale: No item misfit; No dependency of item; scale passed
unidimensionality test
•
SF-MPQ-2 Affective scale: Item 15 misfit; passed unidimensionality test; items had disordered
response threshold that was not resolved; did not fit Rasch model
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Specific-Knee
pain

Very good

-

Very good

+

Very good

+

Very good

+

Very good

-

•

SF-MPQ-2 Total scale score: complete misfit with Rasch Model; several item exhibit dependence
and don't exhibit differentially item function (Turner et al.)52
SF-MPQ-2 Neuropathic subscales:
•
Disorder ‘Tingling’ threshold corrected after collapsing to a 6-interval scale, from an 11-interval
scale; passed unidimensionality test.
•
No item misfit; level of difficulty adequately distributed; acceptable Person fit statistics observed
(x [SD] ¼ –1.17 [1.13] logits)
•
Although corrected, local dependence exhibited between “Burning” and “numbness” items; DIF
observed on “Pain with light touch” item as severity level varies on the CSS scale.
•
Although corrected, person separation index below individual level of discrimination (0.78, against
required 0.85) (Packham et al. 2018.)39
Factor analysis

•

Confirmatory Factor Analysis; hypothesized a four-factor Solution, 3 confirmed (Dworkin et al.)11
•
Continuous Scale; GFI, 0.988; RMSEA, 0.054; SRMR, 0.0268
•
Intermittent Scale; GFI, 0.957; RMSEA, 0.111; SRMR, 0.0459
•
Neuropathic Scale; GFI, 0.889; RMSEA, 0.191; SRMR, 0.0740
•
Affective Scale; GFI, 0.983; RMSEA, 0.129; SRMR, 0.0250
Confirmatory Factor Analysis; Compared a 1-factor, with a 4-factor solution; 4-factor solution
demonstrates better fit; inter-item correlation 0.61-0.88 (Lovejoy et al.)25
1-Factor Solution: TLI = 0.82, CFI = 0.84, SRMR = 0.06, RMSEA = 0.09, AIC = 19129 (poor fit)
4-Factor Solution: TLI = 0.88, CFI =0 .89, SRMR = 0.06, RMSEA = 0.08, AIC = 18983 (best fit)

Specific-CRPS

Doubtful

-

Specific-Back
pain

Very good
Very good
Very good
Very good

+
+
+

Mixed-MSK

Very good

+

•

Exploratory factor analysis; minimum loading factor 0.4; variance accounted 57.49% ; 4 factor
solution supported; Heavy-pain item over load (Adelmanesh et al.)1

Mixed-MSK

Adequate

?

•

Confirmatory factor analysis; 96 Subjects; Support a 4-factor solution; chi-squared= 478, degrees of
freedom = 203; GFI = 0.917; AGFI = 0.894; RMSEA= 0.05) (Maruo et al.)29

Mixed-MSK

Inadequate

+

Specific-Knee
pain

Very good

+

Pooled result: 3 “very good” studies with conflicting evidence (-/+)
GRADE of evidence: High.
Reliability
Internal consistency

Cronbach Alpha:
•
Total scalep: T1= 0.88
•
Subscalesp (Continuous, Intermittent, Affective, Neuropathic): T1 = 0.75 - 0.81 (Kachooei et al.)17
•
•

Total scale: 0.93
Subscales (Continuous, Intermittent, Affective, Neuropathic): 0.77 - 0.84 (Dworkin et al.)11

Specific-Back
pain

Very good

+

•
•

Total scale: 0.96
Subscales (Continuous, Intermittent, Affective, Neuropathic): 0.84 - 0.92 (Lovejoy et al.)25

Mixed-MSK

Very good

+
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•
•
•
•

Total scoreJ: 0.907
SubscalesJ (Continuous, Intermittent, Affective Neuropathic): 0.857 -0.917) (Maruo et al.)29
Total score: 0.95
Subscales (Neuropathic): 0.83 (Packham et al.)39

Mixed-MSK

Very good

+

Mixed-MSK

Very good

+

•

Total scalep: 0.906 (Adelmanesh et al.)1

Mixed-MSK

inadequate

-

Pooled evidence (range): SF-MPQ-2, range for total subscale= 0.88-0.96; range for Subscale score = 0.75-0.92, from 4
studies of “very good” quality
GRADE of evidence: High
Reproducibility;
Test- retest

Intraclass correlation coefficients (ICC):
•
Analyzed with Rasch Model:
•
Normal ICC, for each subscale 0.38 - 0.67
•
Rasch Converted ICC, for each subscale 0.47- 0.63 (Affective subscale excluded) (Turner et al.)52
•
N = 43; Retest-interval = 3 days,

Specific-Knee
pain

Doubtful

-

Specific-Knee
pain

Adequate

+

P

Mixed-MSK

Doubtful

+

J

Mixed-MSK

Doubtful

+

p

•

Total scale = 0.90;

•

Subscales (Continuous, Intermittent, Affective, Neuropathic): 0.73-0.90 (Kachooei et al.)17

•

Total scale ICC = 0.941 (Adelmanesh et al.)1

•

Total scale = 0.83

•

P

J

Subscales (Continuous, Intermittent, Neuropathic, Affective): 0.75-0.85 (Maruo et al.)29

Pooled evidence: ICC range for Total score, 0.90; ICC range for subscales, 0.73-0.90, from one study of “adequate”
quality
GRADE of evidence: Low
Responsiveness;
•

Post knee replacement patient; 6months interval.
Effect Size: Continuous scale, 1.08; Intermittent, 1.12; Neuropathic, 0.15; Affective, 0.78
Rasch converted Effect size: Continuous, 1.27; intermittent, 1.02; neuropathic, 0.09 (Turner et al.)52

•

Neuropathic subscale: Effect Size = 0.92 (CI, 0.53 -1.31); SRM = 0.97 (Packham et al.)39
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Specific-Knee
pain

Inadequate

-

Specific-CRPS

Adequate

?

•

Change in patient status between baseline and day 5, after commencement of treatment was significant
for all subscales of the SF-MPQ-2 and its total score (Dworkin et al.)11
Subscale
continuous
Intermittent
affective
Total

•

Baseline
M(SD)
5.19 (2.19)
5.04 (2.34)
2.94 (2.26)
4.23 (2.05)

Day-5
M(SD)
2.79 (2.13
2.45 (2.15
1.47 (1.69)
2.11 (1.77)

28.22 (SD 8.62)

0.0014

Minimally improved

21.43 (SD 5.40)

0.016

No change

9.33 (SD 6.08)

p-value not
reported

Inadequate

-

Mixed-MSK

Inadequate

-

T-Test value
t(527) = 26.36, P < .01
t(527) = 27.75, P < .01
t(527) = 17.73, P < .01
t(527) = 27.31, P < .01

Non-neuropathic patients mean difference of pre-treatment and Post-Treatment as anchored with
PGIC (Adelmanesh et al.)1
Subscale
M(SD)
P-Value
Very much improved
35.20 (SD 11.43) 0.007
Much Improved

Specific-Back
pain

Pooled evidence: `1 adequate study of indeterminant quality
GRADE of evidence: Very low
Key: WOMAC, Western Ontario and McMaster Universities Arthritis Index; SF-36,Short Form-36 Health Status Questionnaire (PF=Physical Function, BP=Body Pain,
GH=General Health, VT=Vitality, RE=Role Emotion, MCS=Mental Component Summary, PCS=Physical Component Summary); QTFC, Quebec Task Force
Classification for Spinal Disorder; MPI, Multidimensional Pain Inventory; CI, confidence interval; CSS, Complex Regional Pain Syndrome Severity Score; PDI, Pain
Disability Index; BDI-II, Beck Depression Index-Version 2; GAD-7, General Anxiety Disorder 7-item scale; SF-MPQJ, Short form McGill Pain Questionnaire-Japanese
Version; LF-MPQJ, Long Form McGill Pain Questionnaire-Japanese version; PPI, Present Pain Intensity; AIC, Akaike Information Criterion; VAS, Visual Analogy
Scale; HAD; Hospital Anxiety and Depression Scale; NRS, Numerical Rating scale; PGIC, patient global impression of change; AGFI, Adjusted Goodness-of-Fit
Index; CFI, comparative fit index; GFI, goodness-of-fit index; RMSEA, root mean squared error of approximation; SRMR, standardized root mean square residual; M,
Mean; SD, standard deviation CFI comparative fit index; TLI; Tucker-Lewis index; P, Persian version; J, Japanese version
Quality rating Key: (+) = sufficient; (-) = insufficient; (?) = indeterminate; NA = not applicable
Risk of Bias rating: Very good; Adequate; Doubtful; Inadequate
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TABLE 7: COSMIN MODIFIED GRADE LEVEL OF EVIDENCE SYNTHESIS
Brief Pain Inventory-Short form
Measurement
Property

Revised short McGill Pain
Questionnaire Version 2

Interference

Severity

Subscales and Total scores

Is one
instrument
better?

1. Test-retest reliability

High (+)

Low (+)

Low (+)

Yes, BPI-SF

3. Internal consistency

High (+)

High (+)

High (+)

No

4. Responsiveness

High (+)

High (+)

Very low (?)

Yes, BPI-SF

5. Structural validity

High (+)

High (+)

High (+/-)

Yes, BPI-SF

6. Hypothesis testing
(convergent validity)

High (+)

High (+)

High (+)

No

7. Hypothesis testing
(known group validity)

Moderate (+)

Moderate (+)

Very low (?)

Yes, BPI-SF

8. Cross cultural
validity/Measurement
invariance

No evidence

No evidence

No evidence

No evidence

9. Measurement error
(SEM and MDC)

No evidence

No evidence

No evidence

No evidence
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APPENDIX 1
Search concepts adapted, each for the BPI-SF and SF-MPQ-2, on Medline, EMBASE,
CINAHL and Scopus bibliographic databases
A. (“Brief Pain Inventory”) AND (Psychometric OR “Measurement Properties”
OR Validation OR Adaptation OR "Cross-cultural" OR Reliability OR Validity
OR "Internal Consistency" OR Sensitivity OR Specificity OR Discriminative
OR Responsiveness OR "Factor analysis" OR Minimal Clinically Important
Difference OR "Clinically Important difference" OR Rasch)
B. ("McGill Pain Questionnaire") AND (Psychometric OR “Measurement
Properties” OR Validation OR Adaptation OR "Cross-cultural" OR Reliability
OR Validity OR "Internal Consistency" OR Sensitivity OR Specificity OR
Discriminative OR Responsiveness OR "Factor analysis" OR Minimal
Clinically Important Difference OR "Clinically Important difference" OR
Rasch)
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ABSTRACT
Study design: Test-retest.
Background: The Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) is a
multidimensional outcome measure designed to capture, evaluate and discriminate pain from
neuropathic and non-neuropathic sources. A recent systematic review found insufficient
psychometric data with respect to musculoskeletal health conditions.
Objectives: To describe the reproducibility (reliability and agreement) and internal
consistency of the SF-MPQ-2 for use among patients with musculoskeletal shoulder pain.
Methods: Eligible patients with shoulder pain completed the SF-MPQ-2 two times: at
baseline (n=195), and after 3-7days (n= 48), if they remained in stable pain. Cronbach alpha
(α) and intraclass correlation coefficient (ICC2,1), and their related 95% CI were calculated.
The Standard Error of Measurement (SEM), group and individual minimal detectable change
(MDC90) and Bland-Altman (BA) plots were used to assess agreement.
Results: Cronbach α ranged from 0.83 to 0.95 suggesting very satisfactory internal
consistency across the SF-MPQ-2 domains. Excellent ICC2,1 scores were found in support of
the total (0.95) and continuous scale (0.92); the remaining domains displayed good ICC2,1
scores (0.78 -0.88). The Bland-Altman analysis revealed no systematic bias between the test
and retest scores. While the best agreement coefficients were seen on the total scale (SEM =
0.5; MDC90 = 1.2 and MDC90group = 0.3), they were acceptable for the SF-MPQ-2
subscales (SEM: range, 0.7 - 1; MDC90: range, 1.7 - 2.3; MDC90group: range, 0.4 – 0.5).
Conclusion: Good reproducibility supports the SF-MPQ-2 domains for augmented or
independent use in MSK-related shoulder pain assessment, with the total scale displaying the
best reproducibility coefficients. Additional research on the validity and responsiveness of
the SF-MPQ-2 is still required in this population.
Keywords: Reproducibility; Reliability; Agreement; McGill Pain Questionnaire; Shoulder
Pain; Musculoskeletal Conditions; Patient-Reported Outcomes; Psychometric Properties
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INTRODUCTION
Shoulder disorders are among the three leading causes of musculoskeletal pain.29,35
Although present in all age groups, there is evidence of its increasing prevalence as age
increases.9,32 Shoulder disorders come with significant consequences on the socioeconomic
wellbeing of the patient and the society; studies have linked workers’ absenteeism, loss of
job, and poor health-related quality of life (HRQoL) to symptoms associated with shoulder
disorders.9,23,28,42,56
Pain assessment in clinical practice and research often places emphasis on monitoring
pain intensity, even though we know pain is multidimensional and experienced uniquely by
individuals.37 Patients perceive pain in 6 multiple dimensions: physiologic, sensory,
affective, cognitive, behavioral and socio-cultural.3,37 The comprehensive assessment and
monitoring of these dimensions should improve patient care.24 A multidimensional pain
assessment tool that provides a holistic assessment of pain has been recommended by
experts4,19,59 for use in upper extremity conditions, including shoulder disorders.
The Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) is an example
of a general use multidimensional pain tool that comprehensively examines the sensory and
affective dimensions of pain. Dworkin and colleagues14 added seven new items to the former
15 items SF-MPQ to enhance the SF-MPQ-2 ability to explicitly examine both neuropathic
and non-neuropathic pain characteristics. They also replaced the previous 4-point descriptive
rating scale with a 10-item numerical rating scale to enhance its responsiveness.14 Since then,
multiple studies have utilized the improved SF-MPQ-2 as a primary outcome for pain
assessment in clinical trials, and its measurement properties have been examined in different
populations including cancer pain,18 surgical pain,43 visceral pain,58 and neuropathic pain.40
Among MSK conditions, studies have reported measurement evidence examined among
patients with complex regional pain syndrome,45 back pain,15 knee OA,26 and mixed MSK
populations.1,30 Although the SF-MPQ-2 is becoming increasingly popular, our recent
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review25,31 reported on evidence with design flaws including inadequate description of ICC
models, insufficient justification of retest interval, and lack of attention to absolute reliability
parameters.
In the absence of such evidence, the primary purpose of this study was to investigate
the reproducibility (test-retest reliability and agreement) and internal consistency of the
Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) among persons with MSKrelated shoulder problems.
METHODS
This study was based on a test–retest design. The SF-MPQ-2 questionnaire was
administered to examine reproducibility (i.e. relative and absolute reliabilities and internal
consistency) at two time points: at baseline and after 3-7 days (when patients would, for the
most part, be stable).12,34 The participants were recruited from the Roth|McFarlane Hand and
Upper Limb Center, London, ON, Canada over a period of 6-months (June – November
2018). Ethical approval to recruit and review patients’ clinical charts was waived by the
Health Sciences Research Ethics Board of the University of Western Ontario, London,
Ontario, Canada.
Patients
Adults proficient in English, above 18 years of age, that experienced pain from one or
more shoulder conditions of known MSK source were included. Potential participants were
excluded if they had: 1) an unstable cardiorespiratory condition; 2) any history of problems
relating with the central nervous system e.g. hemiplegia; 3) pain resulting from neoplastic or
infectious or vascular disorders or referred from internal organs; 4) any neuropathic pain
symptoms resulting from thoracic outlet syndrome, carpal tunnel syndrome or any peripheral
nerve entrapment, or 5) did not provided consent.
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Procedure
Assessors (SJ and HULC research assistants) identified potentially eligible
participants by reviewing the outpatient appointment list of patients scheduled for a clinical
visit with two shoulder surgeons (KF and AG), a day prior. Potential participants were then
contacted on the day of their clinical appointment to see whether they would be willing to
participate. Consenting persons were screened to ensure all criteria were satisfied, then they
received further explanation of the study’s aims and objectives before the SF-MPQ-2
questionnaire was administered. Each participant was verbally instructed to carefully read
and circle the one number that described their pain experience. In cases where participants
had difficulty with selecting an answer, they were told to choose the answer that comes
closest to describing their pain symptoms. If help was needed with understanding any words
or phrases, or with marking their responses, the assessors assisted. The participants were
instructed to complete all items in the questionnaire. Participants were permitted to withdraw
from the study for any reason at any time. A subset of the participants were randomly
selected to self-complete the SF-MPQ-2 at home after 3-7 days if their pain remained
unchanged. Participants were given stamped envelopes (if they accepted) and instructed to
return the completed questionnaire. A global rating of change scale was administered on both
test-retest occasions and compared to ensure that we only reported on patients with stable
pain (for test-retest). Demographic information including age, hand dominance, primary
cause of shoulder pain and gender were noted in person and from their clinical record.
Outcome Measure
The Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) contains 22items/pain descriptors and 4 subscales/domains that examine pain intensity and quality as
follows: (i) continuous pain (throbbing, cramping, gnawing, aching, heavy, and tender
pain); (ii) intermittent pain (shooting, stabbing, sharp pain, splitting pain, electric-shock, and
piercing pain); (iii) neuropathic pain (hot-burning, cold-freezing, pain caused by light touch,
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itching, tingling or pins and needles, and numbness pain), and (iv) affective pain (tiringexhausting, sickening, fearful, and punishing-cruel). All the items are bounded on a zero
(none) to 10 (worst possible) numerical rating scale. The mean of the 22-items yields the SFMPQ-2 total score, while the mean of the items that comprise each of four-subscales yields
the summary score for the subscale.14,15 Higher subscale or total scores suggest greater pain
symptoms/experience, and more than 2 missing values renders patients’ response to the
questionnaire invalid.15 The SF-MPQ-2 uses a recall period of 7-days, instructing the person
to base their rating on their symptoms in the past week.13
Statistical analyses
The SF-MPQ-2 total and subscale scores were considered as interval variables. Data
quality and screening, including the percentage of missing data, outliers, and presence of
floor/ceiling effects was performed. Respondents with two or more missing items were
excluded, in line with the developers’ instructions.15 Continuous variables were descriptively
summarized using means and standard deviations while percentages were used to report
categorical variables. The data was then examined for normality graphically with histograms,
and statistically with the Shapiro-Wilk test. All statistical analysis were completed with
Microsoft Excel Version 2013 and SPSS statistic for windows, Version 25.0. (Armonk, NY:
IBM Corp, Released 2017).
Floor/ceiling effects
The SF-MPQ-2 was assessed for floor/ceiling effect by identifying the number of
participants with the absolute lowest (0-points = floor) and highest scores (10-points =
ceiling) on its total and subscales. Floor/ceiling effects occurring at the magnitude of 15%
were considered substantial.52
Hypothesis: We expected substantial floor effects on the neuropathic and affective
subscales of the SF-MPQ-2 because they evaluate pain dimensions that are relatively
uncommon in orthopaedic shoulder disorders.
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Cross sectional reliability (Internal consistency)
Internal consistency, the degree of item inter-relatedness/equivalence in a
PROM,11,51,52 was assessed with Cronbach alpha (α) and associated 95% confidence
intervals. A commonly accepted requirement for internal consistency reliability is that it
should be at above 0.7. However, redundancy was established at α > 0.95.50–52
Hypothesis: We expected the SF-MPQ-2 to be internally consistent with Cronbach
alpha (α) at 0.8 or above for its subscale scores, and 0.9 or above for its total scores.
Relative reliability (Test-retest reliability)
The intraclass correlation coefficient (ICC2,1) was used to assess the retest reliability
of the SF-MPQ-2 total and subscales.48 ICC2, 1 with 95% confidence interval (CI) were
computed using the two-way mixed and absolute agreement model, that assumes the patients
were randomly selected but the occasions were fixed choices.47 We chose ICC2,1 absolute
agreement over consistency model because it captures elements of systematic bias and is
preferred for computing absolute reliability indicator. ICC2,1 values for the SF-MPQ-2 total
and subscale scores were considered Negative ≤ 0.49, Doubtful 0.50–0.69, Good 0.70–0.89,
and Excellent 0.90–1.00.36
Hypothesis: We expected adequate ICC2,1 scores for group level analysis at ≥ 0.80
(total score), and ≥ 0.70 (subscale score) as previously reported in the literature.1,26
Absolute reliability (Standard Error of Measurement [SEM] and Minimal Detectable Change
[MDC])
Standard Error of Measurement (SEM) is defined as the standard deviation of errors
of measurement associated with particular test takers scores.22 Table 1 explains the five
equations used for agreement analysis. To define SEMagreement for the SF-MPQ-2 total and
subscales scores, the pooled standard deviation calculated from participants mean responses
to the SF-MPQ-2 domains on both test and retest using equation 122,57 and the respective

93

non-transformed ICC2,1 for the SF-MPQ-2 domain under evaluation was keyed into equation
222,44,57 (Table 1). Further, the proportion of the resulting SEM per domain to the total score
of the scale was calculated to yield the SEM percentage or SEM%, as previously used5,44,49
and interpreted as follows: ≤5% = very good; >5% to ≤10% = good; >10% to <20% =
doubtful; and values above 20% = negative44
The minimal detectable change (MDC) or repeatability coefficient describes the
minimum amount of change that must be seen on a tool scores to be confident that true/real
change has occurred without error after two repeated measure, within the period of the testretest.21 For this study, a 90% confidence interval was estimated for the Minimal Detectable
Change (MDC90). Like the SEM, it is also expressed in the unit of the measure and may be
computed at an individual level (MDC90individual) or for a group (MDC90group)12. We estimated
MDC90individual for the total and subscale scores of the SF-MPQ-2 by entering each scales
SEMagreement into equation 3 (Table 1) assuming the data was normally distributed and free
of systematic error. The MDC90individual confidence interval was then computed from the mean
differences (d) of each subscale using equation 4 (Table 1)5,10,12 To determine the group
level minimal detectable change (MDC90group), which is useful for determining if changes
have occurred in an entire population, equation 5 (Table 1) the formula proposed by de Vet
et al.52,55 was employed. Furthermore, as was estimated for SEM, the proportion of the
resulting MDC coefficient per SF-MPQ-2 domain to the total score of the scale was
computed, as previously done,5,44 to yield the MDC percent score (MDC%) and interpreted
was follows: ≤5% = very good; >5% to ≤10% = good; >10% to <20% = doubtful; and
values above 20% = negative.44
Bland-Altman Plots (BA Plots):
The Bland-Altman method was used to visually examine the agreement between the
test and retest scores.6,7 Scatter plots for the total and subscales scores were each plotted for
the difference between scores obtained at time one and time two of the test-retest interval
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against their mean score for the two time points.6–8,41 We then calculated the mean difference
between the two measurement intervals (the ‘bias’) and the 95% limits of agreement (LOA)
using: LOA = mean difference (d) ± 1.96 SD of the mean differences. The BA plots were
used to visually judge the 95% limits of agreement to determine how well score from
repeated measurements agreed: narrower LOAs suggested better agreement at the individual
level.12,17,41 Agreement at the group level was determined by how close the bias (mean
difference) was to zero. Also, the distribution of scatter points on the BA plots were visually
scrutinized for evidence of variability or heteroscedasticity, where the absence of a linear
relationship between test-retest mean differences and their mean scores, per subscale, suggest
the absence of systematic bias.6–8,41,54,55 Furthermore, linear regression models were used to
explore the presence of systematic bias. For each domain of the SF-MPQ-2, mean scores and
differences in mean scores were modelled as the independent and dependent variables,
respectively. The presence of systematic bias was confirmed by a significant prediction of the
differences by the means scores.41,53 Finally, outliers that presented beyond the upper and
lower boundaries of the LOA were noted and explored.12,16
RESULTS
Figure 1 summarizes the flow of participants through the different phases of the
study. Of the 238 potential patients identified from the review of scheduled appointment list,
195 consenting adults that satisfied the inclusion criteria, provided complete data that was
considered in our analysis of cross-sectional reliability. For the analysis of relative and
absolute reliability, 48 out of 55 stable patients returning completed copies of the SF-MPQ-2
did not have missing data; the mean duration for retest response was 4 days. Table 2
summarizes the characteristic and demographic distribution of the baseline population.
Persons completing this study could be described as an older population, (mean age = 62
years), representing nearly equal proportions of males and females, and presenting with
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different shoulder problems of various MSK pathologies including rotator cuff injuries,
humeral fracture and arthroplasty, and shoulder pain.
Both the graphical and statistical tests of normality revealed the dataset was
skewed/abnormal. To address the assumption of normality for further analysis, a square root
calculation was used to transform the data. A closer look at the reliability coefficients
obtained using the transformed and untransformed data revealed only a very trivial difference
in scores. Because our sample size was large enough, and beyond 30 participants (based on
the central limit theorem), parametric statistics were adopted in our analysis. Despite that, we
still checked for differences in reproducibility coefficients obtained using the transformed
and non-transformed ICC scores (see Table 3 for results).
Floor and ceiling effects
The presence of floor/ceiling effect may suggest an outcome measure is not
responsive to detecting improvement (ceiling effect) even though decline in status can be
captured, and vice versa – for floor effects.15 The number of patients who obtained the
absolute maximum (Ten, 10) and minimal (zero, 0) scores on the SF-MPQ-2 total and
subscales are summarized in Table 3. The greatest level of floor effects was observed on the
affective subscale at both periods of the test-retest. Substantial floor effects were also noted
on the neuropathic and intermittent subscales. None of the SF-MPQ-2 indices had
remarkable ceiling effects.
Reliability
Internal consistency (cross-sectional reliability)
Table 4 summarizes the result obtained for cross sectional reliability. The SF-MPQ-2
displayed excellent internal consistency with robust alpha coefficients presenting within a
range that suggest the absence of redundancy: alpha coefficients for the total subscale peaked
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at 0.95 as posited, while that for the subscales fluctuated around 0.83 to 0.86 points. Interitem correlations were satisfactory, ranging from 0.23-0.53 across the scales.
Relative Test-retest reliability
Good to excellent results were seen in support of test-retest reliability of the SFMPQ-2 domains (Table 5). Our results for ICC2,1 was based on analysis conducted with the
non-transformed data, as they did not differ from that obtained with transformed data. ICC2,1
scores were highest on the continuous and total subscales and rated excellent according to
our criteria. Also, the neuropathic, affective and intermittent subscales displayed good ICC2,1
coefficient (Table 4) in support of relative reliability.
Absolute test-retest reliability (agreement parameters)
Table 5 summarize the absolute reliability coefficients supporting the SF-MPQ-2
domains. The total scale SEMagreement was very low (0.51points) and approximately 5% of the
total score of the scale, which is ‘very good’ according to our criteria. Individual subscale
SEMagreement ranged from 0.73 -0.99 (approximately ≤ 10 % of the total score), which is
‘good’ according to our criteria. At the individual level, acceptable scores within 1.19 – 2.29
points were seen in support of minimal detectable change at 90% confidence level. The best
and worst scores were noted on the total scale (1.19 point, i.e. 11.9% of the total score) and
the intermittent subscale (2.29 point, i.e. 22.9% of the total score), respectively. For Group
MDC90, estimates were acceptable and expectedly lower than those obtained for
MDC90individual; the results fluctuated within 0.28 (total) to 0.54 (intermittent) points across
the SF-MPQ-2 domains (Table 5).
Bland-Altman Analysis/Plots
The results of our Bland–Altman analysis are presented in Table 4. Also, BlandAltman plots superimposed with the LoA and mean difference (bias) scores for each domain
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of the SF-MPQ-2 are graphically illustrated (Figure 2 to 6). All the SF-MPQ-2 domains
displayed acceptable LoA at 95% confidence level with the highest distance ranging 5 points
(intermittent subscale). The total scale score displayed the narrowest LoA (range = 3 points),
with the remaining subscales within satisfactory limits. Mean difference scores (bias) were
very acceptable for all the SF-MPQ-2 domains (0.15 – 0.19 points).
Visual inspection of scatter points on the BA plots for each domain of the SF-MPQ-2
revealed that the magnitude of mean difference against the mean scores were uniformly
distributed from the point of zero and most scatter points were within the 95% Limit of
Agreement but for few outliers. This supports the absence of systematic bias and suggest a
good level of agreement among test-retest scores. Furthermore, for each of the SF-MPQ-2
domains, there was no evidence of the mean difference scores predicting the mean average
after our regression model analysis. This gives more weight to the absence of systematic bias
and confirms good level of agreement between the test-retest scores (Table 5).
The few outliers noted were explored. First, we determined if they were erroneous
responses in entry by rechecking hard copies but, indeed, they were ‘interesting’ outliers 2
and labelled according to their #RS on each BA plot. The greatest number of interesting
outliers presented on the intermittent (n=6, 12.5%) and neuropathic (n=4, 10%) subscales.
The least number of outliers were seen on the affective subscale (n=2, 4.1%). In general,
however, the presence of these outliers did not indicate the presence or absence of bias.2
DISCUSSION
This study provides strong support of the reproducibility of the SF-MPQ-2 for use in
multidimensional pain assessment of people with musculoskeletal shoulder pain. We found
good to excellent reproducibility coefficients in support of internal consistency, relative
reliability and absolute reliability. The limits of agreement for the subscales and total scores
were very satisfactory.
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Although some floor effects can be expected on the neuropathic, intermittent and
affective subscales, we attribute this to the lower prevalence of these problems in our
populations and the high discriminative property of the SF-MPQ-2 subscales. Conceptually,
the SF-MPQ-2 was expanded to provide a single tool that can classify pain from both
neuropathic and nociceptive sources.14,15 As outcome measures can be evaluative or
discriminative, combining both purposes within an outcome measure is likely to result in
these type of issues. For instance, participants with pain emerging from neuropathic sources
are more inclined to respond adequately to the neuropathic subscale with no floor effect, as
has been observed with the use of the SF-MPQ-2 among CRPS patients.45 This implies that
floor effects on the SF-MPQ-2 domains may not always represent redundancy but may
suggest that an item does not describe the patient’s pain experience.25
Cross sectional reliability was established for the SF-MPQ-2 total and subscale scores
with satisfactory coefficients supporting internal consistency in line with previous estimates
among mixed-MSK30 (total, 0.93; subscale, 0.84-0.92), CRPS45 (total, 0.95; neuropathic
subscale, 0.83), knee OA26 (total, 0.88; subscale 0.75-0.81) and acute back pain15 (total, 0.93;
subscale, 0.77-0.84) patient populations. Inter-item correlations were also adequate. The
adequate Cronbach's alpha obtained signifies the absence of redundancy in the domains of
SF-MPQ-2 thus confirming their unidimensionality51 to capture the different pain
characteristics they assess.
In the present study, ICC2,1 coefficients were good to excellent for all the SF-MPQ-2
domain scores (total, 0.93; subscales, 0.78 - 0.91), suggesting they can discriminate patients
adequately at the individual level (total and continuous scale), and at the group level (all the
SF-MPQ-2 domains).12,27 These results are comparable or better than previous findings
reporting estimates among knee OA26 (total, 0.90; subscale, 0.73-0.90) and mixed MSK
patients1,33 (total, 0.90-0.941; subscale, 0.73-0.90). Although acceptable, the low
performance of the neuropathic subscale (0.78), with an ICC score that overlapped the
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‘moderate’ confidence interval threshold suggest less variability on this subscale which
makes it more difficult to achieve a high ICC2,1 score.
Absolute reliability estimates allow clinicians to assess true change in a patient in
comparison to change that might be expected from measurement error.52,55 Currently, no
previous data have examined absolute reliability indices for the SF-MPQ-2 scores in any
population. This makes direct interpretation and comparison difficult; however, our use of
Ostelo et al.44 definition of SEM and MDC by percentages allows comparison across the
domains of the SF-MPQ-2, and with its former version (SF-MPQ). The SEM for the total
score (≤ 5% of total scale score) was ‘very good’ and comparable to that reported for the
former version (SF-MPQ) among OA patients (≤ 3.64%)20 but better than those seen among
mixed MSK patients assessed with the Norwegian version of the SF-MPQ (≤ 10%).49
Although not as favorable as estimates noted on the total subscale, the affective and
intermittent/continuous (or sensory subscale on the previous version) subscales displayed
‘good’ SEM (≤ 10%) that was similar to that seen among OA patient (≤10%)20 or better than
those seen among mixed MSK (≤14%)49 with the previous SF-MPQ version. Basically, SEM
estimates for all the SF-MPQ-2 subscales were satisfactory and suggest an adequate
evaluative capacity that can yield scores less prone to error when utilized by
researchers/clinicians for MSK shoulder pain assessment over time.
The MDC scores represents the minimal change in scores after repeated
administration that clinicians/researchers can interpret is not due to error for an individual or
group in a population.21 The MDC90indivdiual scores obtained for the SF-MPQ-2 domains
implies that change at a magnitude equal or greater than 1.8 (neuropathic), 1.7 (affective), 1.8
(continuous), 2.3 (intermittent), 1.2 (total) points represents genuine improvement beyond
error with 90 percent confidence. The MDC scores for the total scale (≤ 11.9% of the total
score of the scale) were comparable to previous studies with the former version (SF-MPQ)
among OA patients (≤ 11.5%) and better than the results seen among mixed MSK patients (≤
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26.4% of total score). The MDC90group means that change of atleast 0.4 (affective), 0.5
(intermittent), 0.3 (total), 0.4 (neuropathic), 0.4 (continuous) points must be noted for a group
to be 90-percent confident that it is change beyond random or systematic error. In general,
MDC scores are useful when interventions are administered: to be sure the intervention is
effective, it must demonstrate change beyond the MDC score reported for the scale. Also,
MDC90group indices can be used for sample size estimation in a randomized controlled trial, as
they determine the number of participants that will be needed to detect a change on the
measure beyond error for a group, if the Minimal Clinical Important Difference score for the
population is unknown.
The Bland-Altman plots revealed very satisfactory LoA in support of the SF-MPQ-2
subscales. Although the interpretation of how far apart two measurements can be before they
are no longer considered interchangeable depends on the contextual application,41 the LoA
between test-retest of the SF-MPQ-2 domains were reasonably smaller than those seen in
previous studies with its former version (SF MPQ)20,49 and suggest minimal variation
between the occasion of test-retest.54 Furthermore, no bias was found in measurement
between the test-retest, since the inter-occasion mean difference was minimal. This suggests
that learning or test accommodation are not issues with using the SF-MPQ-2; moreover, our
compliance to recommended time intervals (3-7 days)12,34,38 may have favored the agreement
outcomes. The intermittent subscale had the greatest number of outliers of all the BA plots
(12.5%) and may be from the highly volatile nature of the pain descriptors comprising the
scale.
The SF-MPQ-2 total scores displayed the best reproducibility parameters in support
of its relative, absolute and level of agreement parameters. This could be from the number of
items contained in the scale. For instance, better ICC scores can be expected when variability
is low. And among other factors, variability decreases when a greater number of descriptors
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comprise a scale, in comparison to those with fewer descriptors.12 As all 22 items of the SFMPQ-2 contribute to the summary total scale scores, it is possible this favors reproducibility.
STUDY LIMITATIONS AND AREAS FOR FUTURE RESEARCH
While the present study findings provide preliminary evidence supporting the
reproducibility of the SF-MPQ-2 for use in shoulder problems, it has several limitations.
First, the study sample size (48 participants) was just under 50 participants as recommended
by the COSMIN.39,46 Second, the patient population were from a single tertiary referral
practice, hence our findings may not be the same in a less differentiated cohort; it may also
impact on generalizability. Third, since participants completed the retest (Time 2) at home,
we were unable to clarify instructions. However, independent completion is a requirement for
routine administration. Further, the high level of agreement between scores of the tests and
the absence of systematic bias suggest this was not a problem. Fourth, sample mean age was
62 (+ 17.3) years, which may not adequately reflect the reliability of younger populations.
Finally, we did not determine minimal clinically important difference.
CONCLUSION
We conclude that the SF-MPQ-2 provides good to excellent test-retest reliability for
multidimensional pain assessment among patients with musculoskeletal shoulder pain
conditions.
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Figure 1: Flow chart of progress through the phases of screening, recruitment, test, retest and data analysis.

Potential Participants Identified
from Surgeons Appointment
schedules and EMR Chart
(n = 238)

Participant that completed the
SF-MPQ-2 at baseline (Time 1)
(n=208)

Did not meet predefined inclusion
criteria:
1. Did not consent to participate (n= 10)
2. Not English speaking (n = 5)
3. Severe cardiovascular disorder (n = 4)
4. Inpatient booked for surgery (n=11)

Excluded due to missing data when
completing the SF-MPQ-2
(n = 13)

Participants for
Reproducibility Analysis
(n=195)

Participants offered
take-home retest
envelops
(n = 102)
Did not return
Time 2 envelops
(n = 45)
Retest envelops
returned
(n = 55)
Excluded due to
Missing data
(n = 7)
Included in
Cross-sectional reliability
(Internal consistency)
assessment

Included in absolute
(SEM, MDC, BA plots)
and relative (ICC2,1)
reliability assessment

(n = 195)

(n = 48)
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TABLE 1: Summary of Equations Used in Agreement Analysis

EQUATION

FORMULA

1

SD pooled = (SD test + SD retest) / 2

2

SEM agreement = Standard Deviation pooled ×√1 − ICC 2,1

3

MDC90individual = 1.64 × √2 × SEM agreement

4

95% CI for MDC90individual = d ± MDC90individual

5

MDC90group = MDC90individual /√n × 1.64

PURPOSE
For estimating pooled
standard deviation (SD
pooled) from the test and
retest scores. The SD pooled
is among the indices
required for SEMagreement
estimation.
For estimating SEMagreement,
which is important for the
MDC90individual estimation.
For determining the point
estimate of MDC90individual,
which is required for
estimating the confidence
interval range and the
MDC90group scores per
subscale of the SF-MPQ-2
For computing the 90%
confidence interval range
for the MDC90individual score
obtained for each subscale
of SF-MPQ-2
For estimating the MDC90
group score for the entire
population.

Key: SEMagreement, Standard Error of Measurement (agreement); SDtest, Standard Deviation of test
scores; SDretest, Standard deviation of retest scores; SDpooled, pooled Standard Deviation; n, sample
size; CI, confidence interval; MDC90individual, Individual level Minimal Detectable Change at 90%
CI; MDC90group, Group level Minimal Detectable Change at 90% CI; d, mean difference; ICC2,1,
Intraclass correlation coefficient.
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TABLE 2: Patient Baseline Characteristic (N = 195)
Variables

N/%

Age in years (mean + SD)

(62 + 17.3) 195/100%

Shoulder problem
Arthroplasty
Fracture humeral & others
Rotator cuff pathologies
Pain
Dislocation
OA
Impingement/bursitis

39 / 20%
23 / 12%
48 / 25%
40 / 21%
12 / 6%
18 / 9%
15 / 8%

Affected Shoulder
Right
Left
Both

111 / 56%
71 / 36%
13 / 6%

Sex
Males
Females

103 / 53 %
92 / 47%

N, number of patients; SD, Standard deviation
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TABLE 3: Floor and ceiling effects for test-retest scores of the SF MPQ-2
total and subscale scores (N= 48)
Variables

Test

Retest

Floor

Ceiling

Floor

Ceiling

SF-MPQ-2
Continuous

7/48 = 14.6%

0/48 = 0%

4/48 = 8.3%

1/48 = 2.1%

SF-MPQ-2
Intermittent

11/48 = 22.9%

0/48 = 0%

15/48 = 31.3%

0/48 = 0%

SF-MPQ-2
Affective

19/48 = 39.6%

1/48 = 2.1%

20/48 = 41.7%

0/48 = 0%

SF-MPQ-2
Neuropathic

14/48 = 29.2%

0/48 = 0%

11/48 = 22.9%

0/48 = 0%

SF-MPQ-2
Total

3/48 = 6.3%

0/48 = 0%

4/48 = 8.3%

0/48 = 0%

SF-MPQ-2, Revised Short McGill Pain Questionnaire Version-2; %, proportion in percentages
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TABLE 4: Cross-sectional Reliability of the SF-MPQ-2 total and subscale
scores (N=195)
Internal consistency (N=195)
Variables
Cronbach alpha (95% CI)

Inter-item correlation

SF-MPQ-2
Continuous

0.87 (0.84 – 0.90)

0.43 – 0.67

SF-MPQ-2
Intermittent

0.87 (0.84 – 0.90)

0.42 – 0.77

SF-MPQ-2
Neuropathic

0.85 (0.81 – 0.88)

0.32 – 0.81

SF-MPQ-2
Affective

0.83 (0.79 – 0.87)

0.44 – 0.78

SF-MPQ-2
Total

0.95 (0.94 – 0.96)

0.21 – 0.78

SF-MPQ-2, Revised Short McGill Pain Questionnaire Version-2; CI, Confidence Interval
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TABLE 5: Absolute reliability (agreement parameters) of the SF-MPQ2 total and subscale scores (N = 48)
Variables

SEMagreement

SEM
(%)

MDC90 individual
(95% CI)

MDC
(%)

SF-MPQ-2
Continuous

MDC90 group

0.8

7.8

1.8 (-1.6 – 2.0)

18.1

0.4

SF-MPQ-2
Neuropathic

0.8

7.8

1.8 (-1.7 – 1.9)

18.0

0.4

SF-MPQ-2
Intermittent

1.0

9.9

2.3 (-2.1 – 2.4)

22.9

0.5

SF-MPQ-2
Affective

0.7

7.3

1.7 (-1.5 – 1.8)

16.8

0.4

SF-MPQ-2
Total

0.5

5.1

1.2 (-1.0 – 1.4)

11.9

0.3

SF-MPQ-2, Revised Short McGill Pain Questionnaire Version-2; CI, Confidence
Interval; SEM, Standard Error Measurement; MDC, Minimal Detectable Change.
SEM (%) and MDC (%) is expressed as the proportion of the obtained SEMagreement or
MDC90individual of domain represented on the SF-MPQ-2 to the total score of the scale (i.e.
10 points).
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TABLE 6: Relative reliability of the SF-MPQ-2 total and subscale Scores (N = 48)
Test-Retest Reliability
Variables
Single measure ICC2,1 (95% CI)
Test
Mean (SD)

Test
Mean (SD)

d (SD)

95% CI of d

95% LOA

Transformed data

2.8 (2.6)

2.7 (2.6)

0.19 (1.12)

-0.14 – 0.51

-2.01, 2.38

a

0.90 (0.83 – 0.94)

a

SF-MPQ-2
Intermittent

2.1 (2.3)

2.0 (2.4)

0.15 (1.39)

-0.24 – 0.54

-2.58, 2.88

a

0.82 (0.71 – 0.90)

a

SF-MPQ-2
Neuropathic

1.5 (1.6)

1.3 (1.7)

0.13 (1.10)

-0.19 – 0.45

-2.02, 2.28

a

0.78 (0.64 – 0.87)

a

0.78 (0.64 – 0.87)

SF-MPQ-2
Affective

1.5 (1.9)

1.3 (2.0)

0.15 (1.01)

-0.14 – 0.45

-1.83, 2.14

a

0.85 (0.75 – 0.92)

a

0.87 (0.78 – 0.92)

SF-MPQ-2
Total

2.0 (1.9)

1.9 (2.0)

0.15 (0.73)

-0.06 – 0.37

-1.29, 1.59

a

0.92 (0.86 – 0.96)

a

0.93 (0.87 – 0.96)

SF-MPQ-2
Continuous

Non-transformed data
0.91 (0.84 – 0.95)

0.82 (0.71 – 0.90)

SF-MPQ-2, Revised Short-form McGill Pain Questionnaire Version-2; d, Mean difference (test-retest); SD, Standard deviation;
CI, Confidence interval; LOA, Limits of Agreement; ICC, Intraclass Correlation Coefficient.
aAll correlation coefficient (r) were statistically significant at p < 0.001 (2-tailed).
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2.5
2

Difference SF-MPQ-2 Total (Test-retest)

d+1.96SD = 1.59
1.5
1
0.5

d = 0.15
0
-0.5
-1

d-1.96SD = -1.29

-1.5
-2
-2.5
0

1

2

3

4

5

6

Mean SF-MPQ-2 Total (Test-retest)
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3
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Figure 2 to 6 represent the Bland-Altman Limits of Agreement (LOA) plots between the test and retest scores of the SF-MPQ-2 Total (Fig
2), Neuropathic (Fig 3), Intermittent (Fig 4), Continuous (Fig 5) and Affective (Fig 6) subscale scores (n = 48). The difference between testretest scores is plotted against the mean of test and retest scores for the respective SF-MPQ-2 total and subscales depicted. On each plot, the
central blue line represents the mean of intra individual differences (d); the upper and lower horizontal broken lines represent the 95%
LOA. The 95% LOA shows that 95% of the intra individual differences are supposed to within d ± 1.96 SD of mean difference (d). The
outlier noted in each BA plot is numbered, according to participant #RS I.D, and present in accordance to the SF-MPQ-2 subscale or total
they were noted.

122

CHAPTER 4:
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DISCUSSION
Summary
In order to use a patient-reported outcome measure (PROM) in research or clinical
practice, it is important to understand its measurement performance, cost and utility of the
measure (1–4). The Brief Pain Inventory-Short Form (5,6) and Revised Short McGill Pain
Questionnaire Version-2 (7) are general-use multidimensional tools recommended for use
either independently or alongside other measures for comprehensive pain assessment in
musculoskeletal conditions. This thesis examined existing measurement evidence supporting
their use in pain-related musculoskeletal conditions. The first thesis manuscript (chapter 2) was
a systematic review that addressed the quality and content of psychometric evidence
supporting the BPI-SF and SF-MPQ-2 in MSK conditions. The review identified gaps in the
literature (8,9) which informed our second thesis manuscript (chapter 3) study aim of
determining the reproducibility of the SF-MPQ-2. A sample of adults with musculoskeletal
shoulder pain were then recruited to complete the SF-MPQ-2 in two occasions for us to be able
to examine reliability and agreement properties (chapter 3).
The systematic review study (chapter-2) examined the available measurement evidence
reported for the BPI-SF and SF-MPQ-2 in mixed and specific MSK conditions. The search
identified 25-articles addressing both tools properties in MSK conditions, however, more than
half (17-articles) focused of the BPI-SF, perhaps, from its long-time presence in the literature
(10). Because both tools are general-use PROMs (often applicable in any context for pain
assessment), studies reporting psychometrics in mixed and specific MSK populations were
included if MSK conditions represented ≥70% of the sample to enhance the generalizability of
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our findings. Despite our inclusion decisions, we were unable to locate studies examining
psychometric properties for both tools in homogenous upper extremity conditions. The
findings of our evidence synthesis, based on the COSMIN modified GRADE (11), suggest
high-quality evidence supports both tools internal consistency and criterion-convergent
validities in MSK populations. However, the BPI-SF displayed better quality evidence in
support of its responsiveness, test-retest reliability, known group validity and structural
validities over that of the SF-MPQ-2.
Our review identified three important gaps in the literature. First, studies investigating
content validity, cross-cultural equivalence and MCID/CID were lacking for both tools.
Second, evidence backing responsiveness and known group validity were mostly flawed (based
on the COSMIN guidelines). The authors of the included studies did not provide hypotheses
with specific directions and magnitudes of expected change. Third, the reliability assessment
for both tools focused mainly on estimating intraclass correlation coefficients and Cronbach
alpha with no effort towards defining agreement parameters. The first manuscript made
important recommendations for future research and the second manuscript of this thesis
addressed some of the gaps in the literature.
The second research manuscript investigated the reproducibility of the SF-MPQ-2 for
use among patients with musculoskeletal shoulder pain. This second research manuscript
addressed three important gaps in the literature: a) the current dearth in comprehensive
evidence regarding the reproducibility properties of the SF-MQ-2 in MSK conditions; b) the
absence of any measurement evidence backing the SF-MPQ-2 in upper extremity MSK
conditions; c) established the reproducibility of the SF-MPQ-2 for use among patients with
musculoskeletal shoulder pain. As a strength, a representative sample of patients with
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musculoskeletal shoulder pain was captured and a satisfactory retest interval (3-7days), as
recommended in the literature, was used. Furthermore, the stability of patients’ responses was
supported with the concomitant administration of the Global Rating of Change scale. We used
a wide range of statistical approaches to establish the reliability and agreement properties of
the SF-MPQ-2 while adhering to existing guidelines (11–13). The second research study
established acceptable internal consistency, relative reliability (ICC 2,1) and agreement
parameters (SEM and MDC) for the SF-MPQ-2 use in musculoskeletal shoulder pain, and the
Bland-Altman method (14,15) confirmed no evidence of systematic bias between retest
occasions.
Strengths and Limitations of the Two Manuscripts
The main strength of the first manuscript was the rigorous steps taken to reach
conclusions in the review. Two quality assessment processes [COSMIN (1,3,11,13) and
MacDermid’s methods (16)] were completed to reach conclusions on both tools performance
in MSK conditions. Furthermore, we presented evidence distinctively for mixed and specific
MSK population to ensure potential tool users have contextual information on how both tools
performance in peculiar MSK conditions.
Two strengths of the second research study were our reliance on established guidelines
(3,12) and the robustness of our reproducibility analysis. We adhered to established guideline
instructions in choosing an appropriate retest interval (3-7 days) and the used the Global Rating
of Change to determine if patients were in stable pain threshold (17). Also, our statistical
analysis were detailed: we assessed both relative, cross-sectional, and absolute reliability
properties and used the Bland-Altman method to determine reproducibility. We did this to
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ensure confidence in our findings, which influences potential users’ choice for the SF-MPQ-2,
hence encouraging its clinical applicability.
However, this thesis has some limitations. First, we compared both tools even though
they examine slightly different dimensions of pain (BPI-SF = interference; SF-MPQ-2 =
Quality). Second, making conclusions when using the COSMIN Modified GRADE does not
equate to a study that directly compares both tools. Third, even though our review identified
several gaps in the literature, we could only address several issues such as defining the
reproducibility of the SF-MPQ-2 in MSK population. Therefore, future studies should focus on
determining the SF-MPQ-2 validity, responsiveness and structural stability using Rasch
modelling in upper extremity MSK conditions. Finally, our study participants came from a
regional specialty clinic and the generalizability of our findings is not known.
Implications
This thesis has direct implications for research and clinical practice. First, our review
will serve as a useful resource for potential users of the tools including guideline developers,
researchers and clinicians to understand the quality, content and scope of measurement
evidence backing the use of both tools in peculiar and mixed MSK population studies. Second,
although we have shown that the BPI-SF has better psychometric properties than the SF-MPQ2, we suggest that clinicians and researchers should consider the BPI-SF for use, if the
qualities/characteristics of pain are not the primary aim of patients’ assessment. Third,
establishing the reproducibility of the SF-MPQ-2 for use among shoulder pain patients means
researchers and clinicians can be confident that the SF-MPQ-2 yields dependable scores, and
will be a useful tool for multidimensional pain assessment in shoulder pain conditions.
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Future Direction
Our review identified substantial gaps in the literature ranging from methodological
flaws, absence of evidence in upper extremity MSK populations, and the lack of assessment of
some measurement properties. Going forward, studies of the psychometric properties of the
BPI-SF and SF-MPQ-2 in MSK conditions should include:
a) Standard procedures for further establishing reliability that includes defining agreement
parameters in mixed and specific MSK conditions, including upper extremity MSK conditions.
b) A comprehensive assessment of content validity in MSK conditions, bearing in mind that
each tool captures slightly different concepts of pain (SF-MPQ-2= pain quality; BPI-SF = pain
interference). The content analysis could include formal cognitive debriefing and ICF linking
processes.
c) Assessment of responsiveness, minimal detectable differences, and clinically important
differences for both tools in MSK conditions is important. In addition, a clear hypothesis with
direction and expected magnitude should be provided and established anchor/external criterion
should be utilized.
d) Determining the known group validity for both tools in MSK conditions is necessary to
establish the usefulness of the tools. Future studies should employ appropriate statistical
approaches including the use of ROC analysis, and only anchors/external criterions with
established psychometric properties should be utilized in such assessment of known group
validity.
e) Finally, a direct comparison of both tools in various contextual environments should be
conducted.
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In conclusion, this thesis adds to the existing pool of literature regarding the
psychometric and agreement parameters of the Brief Pain Inventory-Short Form and Revised
Short McGill Pain Questionnaire Version 2 in Musculoskeletal Conditions.
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